[go: up one dir, main page]

WO2010085246A1 - 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors - Google Patents

2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors Download PDF

Info

Publication number
WO2010085246A1
WO2010085246A1 PCT/US2009/031575 US2009031575W WO2010085246A1 WO 2010085246 A1 WO2010085246 A1 WO 2010085246A1 US 2009031575 W US2009031575 W US 2009031575W WO 2010085246 A1 WO2010085246 A1 WO 2010085246A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
cycloalkyl
optionally substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/031575
Other languages
French (fr)
Inventor
Yun Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praecis Pharmaceuticals Inc
Original Assignee
Praecis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc
Priority to PCT/US2009/031575 priority Critical patent/WO2010085246A1/en
Publication of WO2010085246A1 publication Critical patent/WO2010085246A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention is directed to compounds that inhibit aggrecanase proteolytic activity which is implicated in joint diseases including osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, rheumatoid arthritis, and other diseases and pathological conditions.
  • the invention is also directed to processes for making the invention compounds, to pharmaceutical compositions, and to methods of treatment osteoarthritis and other joint diseases using the invention compounds.
  • Osteoarthritis is characterized by progressive enzymatic destruction of type II collagen and aggrecan, which are the two major components of cartilage matrix.
  • Type II collagen is essential for cartilage tensile strength and its degradation causes progression of osteoarthritis.
  • Aggrecan is composed of a core protein of approximately 2400 amino acids.
  • the molecule consists of several structural and functional domains (Falnnery et al., Matrix Biology 16, 1998, 507-511). Three domains are defined on the N-terminal side: (1) the Gl, (2) the interglobular, and (3) the G2 domain.
  • the aggrecan C-terminal side comprises two glycosaminoglycan rich domains.
  • the Gl domain is separated from a second globular domain, G2, by about 150 amino acids, known as the interglobular domain. From the G2 domain to the C-terminus there is a long extended region consisting of two glycosaminoglycan-rich domains.
  • the first is rich in keratan sulfate, whereas that which follows is rich in chondroitin sulfate.
  • the Gl domain of aggrecan binds to long hyaluronic acid polymers, thereby forming multi molecular aggregates that effectively immobilize aggrecan within the collagen fibrillar meshwork.
  • the glycosaminoglycan domains provide osmotic pressure, which enables cartilage to resist compression.
  • aggrecan contributes to the progression of osteoarthritis.
  • aggrecan is one of the first cartilage matrix components to undergo measurable loss (Mankin et al., /. Bone Joint Surg. 52A, 424- 434 (1970)).
  • aggrecan degradation is associated with amino acid cleavage within the interglobular domain, at either the Asn 341 -Phe 342 or the GIu 373 - Ala 374 site.
  • NSAIDs have limited symptomatic benefit and have only modest, if any, effects on slowing cartilage destruction in osteoarthritic joints.
  • NSAIDs such as, acetaminophen, act by inhibiting the synthesis of cytokines, such as, prostaglandins that cause pain and swelling. While inhibitors of cartilage degrading enzymes will block cartilage collagen and aggrecan degradation (thereby blocking or slowing the progression of osteoarthritis), NSAIDs do not directly prevent cartilage destruction.
  • Inhibition of aggrecanase should have a more direct and specific effect on cartilage breakdown than cytokine inhibition in the treatment of osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, and rheumatoid arthritis.
  • Y is H, halo, ORi, SRi, (d-C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 -
  • Ri is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 1 is optionally substituted with 1, 2 or 3 (d-C 6 )alkyl, (Ci-C 6 )alkoxy or (Ci-C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ;
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 2 is optionally substituted with 1, 2 or 3 (d-C 6 )alkyl, (Ci-C 6 )alkoxy or (Ci-C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ; or Ri and R 2 can be taken together to form a 5-7 membered heterocycle having 1,
  • R 3 is hydrogen or (Ci -C 6 ) alkyl; m is 0, 1, or 2;
  • X is absent, -CONR 4 -, Or -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (Ci-C 6 )alkyl
  • R 5 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
  • R 12 -N independently selected from R a or 11 in which Rn is hydrogen or (Ci-
  • R 12 is hydrogen, (Ci-C 6 ) alkyl, -CO(d-C 6 )alkyl, -CO(C 1 - C 6 )cycloalkyl, -CO(Ci-C 6 )heterocycloalkyl, -CO(Ci-C 6 ) aryl, -CO(Ci- C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and Ri 2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ;
  • R 6 is hydrogen or (Ci -C 6 ) alkyl;
  • R 7 and Rg are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci-
  • Ce)alkoxy either of which may be optionally substituted on carbon with 1, 2, or
  • Rg is hydrogen, halo or (Ci-C 6 )alkyl
  • R 10 is hydrogen or (Ci-Ce)alkyl
  • Rg and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (Ci-C 6 )alkyl, and -O-(d-C 6 )alkyl, -S-(d-C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Ci-Ce)alkyl, or (Ci-C 6 )alkoxy;
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (C 1 - C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )alkyl]
  • R 1 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 1 is optionally substituted with 1, 2 or 3 (C r C 6 )alkyl, (C r C 6 )alkoxy or (C r C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ;
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 2 is optionally substituted with 1, 2 or 3 (d-C 6 )alkyl, (Ci-C 6 )alkoxy or (Ci-C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ; or Ri and R 2 can be taken together to form a 5-7 membered heterocycle having 1,
  • R 3 is hydrogen or (Ci-C 6 )alkyl; m is 0, 1, or 2;
  • X is absent, -CONR 4 -, Or -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (Ci-C 6 )alkyl
  • R 5 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
  • R 12 -N independently selected from R a or 11 in which Rn is hydrogen or (Ci-
  • R 12 is hydrogen, (Ci-C 6 ) alkyl, -CO(Ci-C 6 )alkyl, -CO(Ci-
  • R 6 is hydrogen or (Ci -C 6 ) alkyl
  • R 7 and R 8 are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci-
  • R 9 is hydrogen, halo or (Ci -C 6 ) alkyl
  • Rio is hydrogen or (Ci-C 6 )alkyl
  • R 9 and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (Ci-C 6 )alkyl, and -O-(Ci-C 6 )alkyl, -S-(Ci-C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Ci-C 6 )alkyl, or (Ci-C 6 )alkoxy;
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (Ci- C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )alkyl]a
  • the invention is directed to a compound of formula
  • Y is H, halo, OR 1 , SR 1 , (C r C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 - C 6 )heterocycloalkyl, heteroaryl, heteroaralkyl, or NR 1 R 2 ;
  • R 1 is hydrogen, (C 1 -C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(C 1 - Ce)alkyl, heteroaryl, heteroaralkyl, (C 1 -Ce)carboxyalkyl, ary 1OXy(C 1 -Ce)alkyl, -
  • R 2 is hydrogen, (C 1 -C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(C 1 -C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(C 1 - Ce)alkyl, heteroaryl, heteroaralkyl, (C 1 -Ce)carboxyalkyl, ary 1OXy(C 1 -Ce)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C 1 - Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2,
  • R 3 is hydrogen or (Ci-C 6 )alkyl; m is O, I, or 2;
  • R 4 is hydrogen or (Ci-C 6 )alkyl
  • R 6 is hydrogen or (Ci-C 6 )alkyl
  • R 7 and R 8 are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci-
  • Ce)alkoxy either of which may be optionally substituted on carbon with 1, 2, or
  • R 9 is hydrogen, halo or (Ci-C 6 )alkyl
  • Rio is hydrogen or (Ci-C 6 )alkyl
  • R 9 and Ri 0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (C r C 6 )alkyl, and -O-(C r C 6 )alkyl, -S-(C r C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl;
  • B t is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl
  • Rn is hydrogen or (Ci-C 6 ) alkyl
  • R J2 is hydrogen, (Ci-C 6 ) alkyl, -CO(Ci- C 6 )alkyl, -CO(Cj -C 6 )cycloalkyl, -CO(Ci-C 6 )heterocycloalkyl, -CO(Ci-C 6 ) aryl, - CO(Ci-C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and Ri 2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ; at least two of three of Zi, Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Ci-C 6 )alkyl, or (Ci-
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (Ci- C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (C r C 6 )alkylamino, di-[(C r C 6 )alkyl]a
  • the invention is directed to a compound of formula
  • Y is H, halo, ORi, SRj, (d-C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 - C 6 )heterocycloalkyl, heteroaryl, heteroaralkyl, or NRiR 2 ;
  • Ri is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-djcarboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", wherein R
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 1 and R 2 can be taken together to form a 5-7 membered heterocycle having 1,
  • R 3 is hydrogen or (C 1 -Ce)alkyl; m is O, I, or 2;
  • X is absent, -CONR 4 -, Or -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (C ⁇ C 6 ) alkyl
  • R 5 is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
  • R 12 -N independently selected from R a or 11 in which R 11 is hydrogen or (C 1 -
  • R 12 is hydrogen, (C 1 -C 6 ) alkyl, -CO(C 1 -C 6 )alkyl, -CO(C 1 - C 6 )cycloalkyl, -COtd-Ce ⁇ eterocycloalkyl, -CO(C 1 -C 6 ) aryl, -CO(C 1 - C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R 11 and R 12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ; R 6 is hydrogen or (Ci-C 6 )alkyl; n is 0, 1, 2 or 3; R 7 and Rg are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci- Ce)alkoxy, either of which may be
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (C 1 - C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )alkyl]
  • the invention is directed to a compound of any of formulae I-IV, wherein the compound is selected from:
  • the invention is directed to a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I- IV, or a pharmaceutically acceptable salt thereof.
  • the invention is directed to a method for treating or preventing an inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutically acceptable salt thereof comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof.
  • the invention is directed to a method of treating a subject suffering from osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, or rheumatoid arthritis, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof.
  • a compound disclosed herein e.g., a compound of formulae I-IV
  • the invention is directed to a process for making a compound disclosed herein, e.g., a compound of formulae I-IV, comprising the steps outlined in Schemes 1-8 infra.
  • Halogen means fluoro, chloro, iodo, and bromo.
  • Alkyl includes both straight and branched chain alkyl groups.
  • Ce)alkyl means an alkyl group having 6 carbon atoms.
  • alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t- pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.
  • alkylene used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
  • Cycloalkyl means a partially or fully saturated ring ring system. "(C 3 -
  • C 7 )cycloalkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Heterocycloalkyl means a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s).
  • Heterocycle may be saturated or partially unsaturated and may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween.
  • (Ci-C 6 )AIkOXy refers to alkyl, alkenyl, and alkynyl groups as defined above that are attached to O. Examples include methoxy, ethoxy, vinyloxy, allyloxy, ethynyloxyy, and 2-propynyloxy.
  • (Ci-C 6 )Alkylthio means an alkyl group attached to S. Examples include methylthio, ethylthio and propylthio.
  • (Ci-C 6 )Alkylsulfinyl means an alkyl group attached to SO. Examples include methylsulphinyl and ethylsulphinyl.
  • (Ci-C 6 )Alkylsulfonyl means an alkyl group attached to SO . Examples include methylsulfonyl and ethylsulfonyl.
  • Amino means NH .
  • (Ci-C 6 )Alkylamino means (C r C 6 )alkyl-NH. Examples include methylamino, ethylamino, propylamino, isopropylamino and butylamino.
  • ((Ci-C 6 )Alkyl) amino means ((Ci-C 6 )alkyl) -N. Examples include dimethylamino, diethylamino, N-ethyl- N-methylamino and diisopropylamino.
  • Carboxy means CO H.
  • (Ci-C 6 )Alkoxycarbonyl means CO (d-C 6 )alkyl. Examples include methoxycarbonyl, ethoxycarbonyl, propoxy- carbonyl and tert-butoxycarbonyl.
  • Examples include N,N- dimethylcarbamoyl, and N,N-diethylcarbamoyl.
  • (Ci-C 6 )alkyl examples include N-methylacetamido and N-methylpropionamido.
  • N-(Ci -C 6 )alkylsulfamoyl means SO 2 -NH(Ci-C 6 )alkyl. Examples include N-methylsulfamoyl and N-ethyl-sulphamoyl.
  • N,N-di-(Ci-C 6 )alkylsulfamoyl means SO 2 -N((Ci-C 6 )alkyl) 2 . Examples include N,N, dimethylsulfamoyl.
  • (Ci-C 6 )alkylsulfonylamino means -NH-SO 2 -(C r C 6 )alkyl.
  • Arylsulfonylamino means -NH-SO 2 -aryl.
  • Aryl means an optionally substituted monocyclic or bicyclic ring system containing at least one aromatic ring. Examples and suitable values of the term
  • aryl are phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indyl and indenyl.
  • Heteroaryl means an optionally substituted monocyclic or bicyclic ring systemcontaining at least one aromatic ring and at least one heteroatom selected independently from N, O or S.
  • heteroaryl include thiophene, thienyl, pyridyl, thiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl and thiadiazolyl, benzoimidazolyl, benzooxazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, indolyl, isoindolyl, pyridonyl, pyridazinyl,
  • alkyl refers to a substituent that is attached via the alkyl group to an aryl, heteroaryl or cycloalkyl group.
  • a "5- or 6-membered ring” refers to aromatic and heteroaromatic rings, as well as carbocyclic and heterocyclic rings, which may be partially or fully saturated.
  • Such rings include, but are not limited to furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl, cyclopentyl and cyclohexenyl.
  • the phrase "pharmaceutically acceptable salts” means derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from nontoxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, trifluoroacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, trifluoroacetic, propionic, succ
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the normal valency of the designated atom is not exceeded, and that the substitution results in a stable compound.
  • any variable such as n, x, R', or R a occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
  • that group may optionally be substituted with up to two R 6 groups and R 6 at each occurrence is selected independently from the definition of R 6 .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a therapeutically effective amount of a compound of the invention may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound are outweighed by the therapeutically beneficial effects.
  • a therapeutically effective amount of a compound of the invention may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0. 1 to 30 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
  • an effective dosage may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0. 1 to 30 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.
  • the skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present, if any.
  • treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, preferably, can include a series of treatments.
  • a subject is treated with a compound of the invention in the range of between about 0.1 and 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks.
  • the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.
  • the present invention is directed to compounds of formula I:
  • Y is H, halo, ORi, SRi, (d-C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 -
  • Ri is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R a 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C 6 )alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C 6 )alkyl, (Ci-C 6 )alkoxy or (Ci-C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ;
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 -
  • R 2 is optionally substituted with 1, 2 or 3 (C r C 6 )alkyl, (C r C 6 )alkoxy or (C r C 6 )haloalkyl or 1, 2 or 3 groups independently selected from R a ; or Ri and R 2 can be taken together to form a 5-7 membered heterocycle with 1, 2 or 3 heteroatoms and optionally substituted with R a ;
  • R 3 is hydrogen or (Ci-C 6 )alkyl; m is O, 1, or 2;
  • X is absent, -CONR 4 - -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (Ci-C 6 )alkyl
  • R 5 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups R 12 -N independently selected from R a or 11 in which R 11 is hydrogen or (C 1 -
  • R 12 is hydrogen, (C 1 -C 6 ) alkyl, -CO(C r C 6 )alkyl, -CO(C 1 -
  • R 11 and R 12 can be taken together to form a 5-7 membered heterocycle having 1, 2, or 3 heteroatoms and optionally substituted with R a ;
  • R 6 is hydrogen or (C 1 -C 6 ) alkyl
  • R 7 and R 8 are each independently hydrogen, halogen, (C 1 -C 6 )alkyl or (C 1 -
  • R 9 is hydrogen, halo or (C 1 -C 6 ) alkyl
  • R 1O is hydrogen or (Q-C ⁇ alkyl
  • R 9 and R 10 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (C r C 6 )alkyl, and -O-(C r C 6 )alkyl, -S-(C r C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z 1 , Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Q-C ⁇ alkyl, or (Q-C ⁇ alkoxy;
  • Y is selected from the group consisting of H, halo,
  • Y is H. In some embodiments, Y is Cl. In some embodiments, Y is OH. In some embodiments, Y is OMe. In some embodiments, Y is -NRiR 2 , e.g., a compound of formula II.
  • Ri is selected from the group consisting of hydrogen and (Ci-C 6 )alkyl.
  • R 3 is hydrogen. In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl.
  • R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is propyl. [00064] In some embodiments, R 5 is methyl. In some embodiments, R 5 is ethyl. In
  • R 5 is phenyl. In some embodiments, R 5 is ⁇ wherein
  • R 5 is aryl optionally
  • -X-R 5 is -SO 2 CH 3 . In some embodiments, -X-R 5 is -COOH. In some embodiments, -X-R 5 is
  • Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, Ri 2 is hydrogen. In some embodiments, Ri 2 is methyl.
  • Ri 2 is heteroaryl optionally substituted with 1 group selected from R a . In some embodiments, Ri 2 is thiadiazole optionally substituted with 1 group selected from R a . In some embodiments, Ri 2 is-COCH 3 .
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2. [00067] In some embodiments, R 6 is methyl. In some embodiments, R 6 is fluoro.
  • R 6 is chloro. In some embodiments, R 6 is hydrogen.
  • R 7 is hydrogen. In some embodiments, R 7 is methoxy. In some embodiments, R 7 is methyl. In some embodiments, R 7 is halogen. In some embodiments, R 7 is chloro.
  • Rg is hydrogen. In some embodiments, Rg is methoxy. In some embodiments, R 8 is methyl. In some embodiments, R 8 is halogen. In some embodiments, R 8 is chloro.
  • Rg is hydrogen. In some embodiments, Rg is methyl. In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is methyl.
  • Rg and Rio are taken together to form a 5-6 membered ring.
  • pyridyl In some embodiments, is cyclohexyl.
  • i -s In some embodiments, M ⁇ v, is .
  • Z 1 is N.
  • Z 2 is N.
  • Z 3 is N.
  • each Of Z 1 , Z 2 and Z 3 are independently N.
  • X is -SO 2 -.
  • X is -CONR 4 -
  • X is -COO-. In some embodiments, X is -SO 2 NR 4 - [00074] In some embodiments, R a is fluoro. In some embodiments, R a is chloro.
  • R a is methyl. In some embodiments, R a is ethyl. In some embodiments, R a is trifluoromethyl. In some embodiments, R a is methoxy. In some embodiments, R a is ethoxy. In some embodiments, R a is trifluoromethoxy. In some embodiments, R a is cyano. In some embodiments, R a is nitro. In some embodiments, R a is hydroxyl. In some embodiments, R a is amino. In some embodiments, R a is -NHCH 3 . In some embodiments, R a is -N(CH 3 ) 2 . In some embodiments, R a is phenyl.
  • R a is CON(CH 3 ) 2 . In some embodiments, R a is OC(O)(CH 3 ). In some embodiments, R a is -OC(O)NH 2 . In some embodiments, R a is -OC(O)NH(CH 3 ). [00075] In some embodiments, R c is chloro. In some embodiments, R c is fluoro.
  • R c is methyl. In some embodiments, R c is trifluoromethyl. In some embodiments, R c is trifluoromethoxy. In some embodiments, R c is cyano. In some embodiments, R c is nitro. In some embodiments, R c is hydroxyl. [00076] In one embodiment, the compounds of the invention are compounds of formula IA
  • the compounds of the invention are compounds of formula IA-i
  • the compounds of the invention are compounds of formula IB
  • compounds of the invention are compounds of formula IC
  • compounds of the invention are compounds of formula ID
  • compounds of the invention are compounds of formula IE
  • compounds of the invention are compounds of formula IF
  • compounds of the invention are compounds of formula IG
  • compounds of the invention are compounds of formula IH
  • compounds of the invention are compounds of formula IJ
  • compounds of the invention are compounds of formula IJ-i
  • compounds of the invention are compounds of formula IK
  • compounds of the invention are compounds of formula IK-i
  • compounds of the invention are compounds of formula IK-ii
  • compounds of the invention are compounds of formula IK-iii
  • compounds of the invention are compounds of formula IL
  • compounds of the invention are compounds of formula IL-i
  • compounds of the invention are compounds of formula IM
  • compounds of the invention are compounds of formula IM-i
  • the compounds of the invention are compounds of formula IN
  • the compounds of the invention are compounds of formula IO
  • compounds of the invention are compounds of formula IP
  • the compounds of the invention are compounds of formula IQ
  • R 5 is hydrogen. In some embodiments, R 5 is methyl.
  • the compounds of the invention are compounds of formula IR
  • R 5 is hydrogen. In some embodiments, R 5 is methyl.
  • R 1 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' "
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C 1 - C 6 )alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-
  • X is absent, -CONR 4 -, Or -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (Ci-C 6 )alkyl;
  • R 5 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
  • R 12 -N independently selected from R a or 11 in which R 11 is hydrogen or (C 1 -
  • R 12 is hydrogen, (C 1 -C 6 ) alkyl, -CO(C 1 -C 6 )alkyl, -CO(C 1 - C 6 )cycloalkyl, -COtQ-Cejlieterocycloalkyl, -CO(C 1 -C 6 ) aryl, -CO(C 1 - C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R 11 and R 12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ; R 6 is hydrogen or (C ⁇ C 6 ) alkyl; R 7 and Rg are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci-
  • Ce)alkoxy either of which may be optionally substituted on carbon with 1, 2, or
  • Rg is hydrogen, halo or (Ci-C 6 )alkyl
  • R 10 is hydrogen or (Ci-Ce)alkyl
  • Rg and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (Ci-C 6 )alkyl, and -O-(d-C 6 )alkyl, -S-(d-C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Ci-Ce)alkyl, or (Ci-C 6 )alkoxy;
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (Ci-C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (C 1 - C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )alkyl]
  • Ri is selected from the group consisting of hydrogen and (Ci-C 6 )alkyl. In some embodiments, Ri is hydrogen. In some embodiments, Ri is methyl. In some embodiments, Ri is ethyl. [000103] In some embodiments, R 2 is methyl. In some embodiments, R 2 is isopropyl. In some embodiments, R 2 is cyclohexyl. In some embodiments, R 2 is benzyl.
  • R 2 is phenyl. In some embodiments, R 2 is wherein "— " indicates the point of attachment. In some embodiments, R 2 is
  • R 2 is , wherein "— " indicates the point of attachment.
  • R 3 is hydrogen. In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl.
  • R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is propyl. [000106] In some embodiments, R 5 is methyl. In some embodiments, R 5 is ethyl.
  • R 5 is phenyl. In some embodiments, R 5 is wherein "— " indicates the point of attachment. In some embodiments, R 5 is aryl
  • R 12 -N optionally substituted with 1 group selected from R a or 11 .
  • -X-R 5 is -SO 2 CH 3 .
  • -X-R 5 is -COOH.
  • -X-R 5 is -C(CH 3 ) 3 .
  • Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, R 12 is hydrogen. In some embodiments, R 12 is methyl. In some embodiments, R 12 is heteroaryl optionally substituted with 1 group selected from R a . In some embodiments, R 12 is thiadiazole optionally substituted with 1 group selected from R a .
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
  • R 6 is methyl. In some embodiments, R 6 is fluoro.
  • R 6 is chloro. In some embodiments, R 6 is hydrogen.
  • R 7 is hydrogen. In some embodiments, R 7 is methoxy. In some embodiments, R 7 is methyl. In some embodiments, R 7 is halogen. In some embodiments, R 7 is chloro.
  • R is hydrogen. In some embodiments, R is
  • R is methyl. In some embodiments, R is halogen. In
  • R is chloro
  • R 9 is hydrogen. In some embodiments, R 9 is methyl. In some embodiments, Rio is hydrogen. In some embodiments, Rio is methyl. In some embodiments, R 9 and Ri 0 are taken together to form a 5-6 membered ring.
  • pyridyl In some embodiments, is cyclohexyl.
  • I iSs N . IInn some embodiments,
  • Z 3 2 is N In some embodiments, Z 3 2 is ⁇ s ⁇ . In some embodiments, Zi is N. In some embodiments, Z 2 is N. In some embodiments, Z 3 is N. In some embodiments, each of Zi, Z 2 and Z 3 are independently N. [000115] In some embodiments, X is -SO 2 -. In some embodiments, X is -CONR 4 - . In some embodiments, X is -COO-. In some embodiments, X is -SO 2 NR 4 -. [000116] In some embodiments, R a is fluoro. In some embodiments, R a is chloro. In some embodiments, R a is methyl. In some embodiments, R a is ethyl.
  • R a is trifluoromethyl. In some embodiments, R a is methoxy. In some embodiments, R a is ethoxy. In some embodiments, R a is trifluoromethoxy. In some embodiments, R a is cyano. In some embodiments, R a is nitro. In some embodiments, R a is hydroxyl. In some embodiments, R a is amino. In some embodiments, R a is -NHCH 3 . In some embodiments, R a is -N(CH 3 ) 2 . In some embodiments, R a is phenyl. In some embodiments, R a is pyridyl.
  • R a is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R a is vinyl, propenyl, or butenyl.
  • R a is acetylenyl, propynyl or butynyl.
  • R a is methylthio.
  • R a is methylsulfinyl.
  • R a is methylsulfonyl.
  • R a is formyl.
  • R a is -OC(O)NH 2 . In some embodiments, R a is -OC(O)NH(CH 3 ).
  • R c is chloro. In some embodiments, R c is fluoro. In some embodiments, R c is methyl. In some embodiments, R c is trifluoromethyl. In some embodiments, R c is trifluoromethoxy. In some embodiments, R c is cyano. In some embodiments, R c is nitro. In some embodiments, R c is hydroxyl. [000118] In one embodiment, compounds of the invention are compounds of formula HA
  • compounds of the invention are compounds of formula HB or pharmaceutically acceptable salts thereof.
  • compounds of the invention are compounds of formula HC
  • compounds of the invention are compounds of formula HD
  • compounds of the invention are compounds of formula HE
  • compounds of the invention are compounds of formula HF
  • compounds of the invention are compounds of formula HG
  • compounds of the invention are compounds of formula IIH
  • compounds of the invention are compounds of formula IU or pharmaceutically acceptable salts thereof.
  • compounds of the invention are compounds of formula HK
  • compounds of the invention are compounds of formula HL
  • compounds of the invention are compounds of formula IIM
  • compounds of the invention are compounds of formula UN
  • the invention is directed to a compound of formula
  • Y is H, halo, ORi, SRi, (d-C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 - C 6 )heterocycloalkyl, heteroaryl, heteroaralkyl, or NR 1 R 2 ;
  • Ri is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", where
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R"
  • R 3 is hydrogen or (Ci-C 6 )alkyl; m is O, I, or 2;
  • R 4 is hydrogen or (Ci -C 6 ) alkyl
  • R 6 is hydrogen or (Ci-C 6 )alkyl
  • R 7 and R 8 are each independently hydrogen, halogen, (Ci-C 6 )alkyl or (Ci-
  • Ce)alkoxy either of which may be optionally substituted on carbon with 1, 2, or
  • R 9 is hydrogen, halo or (Ci -C 6 ) alkyl; Rio is hydrogen or (Ci-C 6 )alkyl; or
  • R 9 and Ri 0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
  • (Ci-C 6 )alkyl, and -O-(d-C 6 )alkyl, -S-(d-C 6 )alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C O; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl;
  • B is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl
  • Rn is hydrogen or (Ci-C 6 ) alkyl
  • R J2 is hydrogen, (Ci-C 6 ) alkyl, -CO(Ci- C 6 )alkyl, -CO(Cj -C 6 )cycloalkyl, -CO(Ci-C 6 )heterocycloalkyl, -CO(Ci-C 6 ) aryl, - CO(Ci-C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and R 12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ; at least two of three of Z 1 , Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (Ci-C 6 )alkyl, or (C
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C 6 )alkyl-NH, ((Ci-C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C r C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (C 1 - C 6 )alkynyloxy, (C r C 6 )alkylthio, (C r C 6 )alkylsulfinyl, (C r C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )alkyl]
  • Y is selected from the group consisting of H, halo, OR 1 , (CrC 8 )alkyl, and NR 1 R 2 .
  • Y is H.
  • Y is Cl.
  • Y is OH.
  • Y is OMe.
  • Y is -NRiR 2 .
  • R 1 is selected from the group consisting of hydrogen and (Ci-C 6 )alkyl.
  • Ri is hydrogen.
  • Ri is methyl.
  • Ri is ethyl.
  • R 2 is methyl.
  • R 2 is isopropyl.
  • R 2 is cyclohexyl.
  • R 2 is benzyl.
  • R 2 is phenyl. In some embodiments, R 2 is wherein "— " indicates the point of attachment. In some embodiments, R 2 is
  • R 2 is ' , wherein "— " indicates the point of attachment.
  • R 3 is hydrogen. In some embodiments, R 3 is methyl. In some embodiments, R 3 is ethyl.
  • R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is propyl.
  • Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, Ri 2 is hydrogen. In some embodiments, Ri 2 is methyl.
  • R 12 is heteroaryl optionally substituted with 1 group selected from R a .
  • Ri 2 is thiadiazole optionally substituted with 1 group selected from R a .
  • R 12 is -COCH 3 .
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
  • R 6 is methyl. In some embodiments, R 6 is fluoro.
  • R 6 is chloro. In some embodiments, R 6 is hydrogen.
  • R 7 is hydrogen. In some embodiments, R 7 is methoxy. In some embodiments, R 7 is methyl. In some embodiments, R 7 is halogen. In some embodiments, R 7 is chloro.
  • R 8 is hydrogen. In some embodiments, R 8 is methoxy. In some embodiments, R 8 is methyl. In some embodiments, R 8 is halogen. In some embodiments, R 8 is chloro. [000143] In some embodiments, Rg is hydrogen. In some embodiments, Rg is methyl. In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is methyl. In some embodiments, R 9 and R 10 are taken together to form a 5-6 membered ring.
  • pyridyl In some embodiments, is cyclohexyl. In some embodiments, is
  • — is pyridyl. In some embodiments, — is cyclohexyl.
  • IInn is IInn : some embodiments,
  • Z 3 2 is N In some embodiments, Z 3 2 is ⁇ s ⁇ . In some embodiments, Zi is N. In some embodiments, Z 2 is N. In some embodiments, Z 3 is N. In some embodiments, each Of Z 1 , Z 2 and Z 3 are independently N. [000146] In some embodiments, X is -SO 2 -. In some embodiments, X is -CONR 4 - . In some embodiments, X is -COO-.
  • R a is fluoro. In some embodiments, R a is chloro. In some embodiments, R a is methyl. In some embodiments, R a is ethyl. In some embodiments, R a is trifluoromethyl. In some embodiments, R a is methoxy. In some embodiments, R a is ethoxy. In some embodiments, R a is trifluoromethoxy. In some embodiments, R a is cyano. In some embodiments, R a is nitro. In some embodiments, R a is hydroxyl. In some embodiments, R a is amino. In some embodiments, R a is -NHCH 3 .
  • R a is -N(CHs) 2 . In some embodiments, R a is phenyl. In some embodiments, R a is pyridyl. In some embodiments, R a is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R a is vinyl, propenyl, or butenyl. In some embodiments, R a is acetylenyl, propynyl or butynyl. In some embodiments, R a is methylthio. In some embodiments, R a is methylsulfinyl. In some embodiments, R a is methylsulfonyl.
  • R a is CON(CH 3 ) 2 . In some embodiments, R a is OC(O)(CH 3 ). In some embodiments, R a is -OC(O)NH 2 . In some embodiments, R a is -OC(O)NH(CH 3 ). [000148] In some embodiments, R c is chloro. In some embodiments, R c is fluoro. In some embodiments, R c is methyl. In some embodiments, R c is trifluoromethyl. In some embodiments, R c is trifluoromethoxy. In some embodiments, R c is cyano. In some embodiments, R c is nitro. In some embodiments, R c is hydroxyl. [000149] In one embodiment, compounds of the invention are compounds of formula IIIA
  • compounds of the invention are compounds of formula IIIB
  • compounds of the invention are compounds of formula IIIC
  • compounds of the invention are compounds of formula HID
  • compounds of the invention are compounds of formula HIE
  • compounds of the invention are compounds of formula IIIF
  • compounds of the invention are compounds of formula IIIG or pharmaceutically acceptable salts thereof.
  • the invention is directed to a compound of formula
  • Y is H, halo, ORi, SRi, (d-C 8 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, aralkyl, (C 3 - C 6 )heterocycloalkyl, heteroaryl, heteroaralkyl, or NR 1 R 2 ;
  • Ri is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", where
  • R 2 is hydrogen, (Ci-C 6 )alkyl, aryl, aralkyl, (C 3 -C 6 )cycloalkyl, (C 3 - C 6 )cycloalkyl(Ci-C 6 )alkyl, (C 3 -C 6 )heterocycloalkyl, (C 3 -C 6 )heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C 6 )carboxyalkyl, aryloxy(Ci-C 6 )alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R"
  • R 3 is hydrogen or (Ci-C 6 )alkyl; m is O, I, or 2;
  • X is absent, -CONR 4 -, Or -SO 2 -, -SO 2 NR 4 -, or -COO-;
  • R 4 is hydrogen or (Ci-C 6 )alkyl
  • R 5 is hydrogen, (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
  • R 12 -N independently selected from R a or 11 in which R 11 is hydrogen or (C 1 -
  • R 12 is hydrogen, (C 1 -C 6 ) alkyl, -CO(C 1 -C 6 )alkyl, -CO(C 1 - C 6 )cycloalkyl, -CO(C 1 -C 6 ) aryl, -CO(C 1 - C 6 )heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R 11 and R 12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with R a ; R 6 is hydrogen or (Ci-C 6 )alkyl; n is 0, 1, 2 or 3;
  • R 7 and Rg are each independently hydrogen, halogen, (C 1 -C 6 )alkyl or (C 1 - C 6 )alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
  • R 3 groups independently selected from R a ; is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z 1 , Z 2 , and Z 3 are N and the other is C-R b , wherein R b is hydrogen, halogen, (CrC ⁇ jalkyl, or (CrC ⁇ jalkoxy;
  • R a is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (C 1 -C 6 )alkyl-NH, ((C 1 -C 6 )alkyl) 2 -N, aryl, heteroaryl, (C 3 -C 7 )cycloalkyl, (C 1 - C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkoxy, (C 2 -C 6 )alkenyloxy, (C 1 - C 6 )alkynyloxy, (Ci-C 6 )alkylthio, (Ci-C 6 )alkylsulfinyl, (Ci-C 6 )alkylsulfonyl, amino, (Ci-C 6 )alkylamino, di-[(Ci-C 6 )al
  • the invention is directed to a compound of any of formulae I-III , wherein the compound is selected from:
  • ADAM TS4 Fluorogenic Assay The biological activity of exemplary compounds disclosed herein was measured using an assay as disclosed in Zhang, Y. et al (2004) Journal of Pharm. And Exp. Therapeutics 309(1): 348-355, the entire contents of which are incorporated herein by reference.
  • the ADAM TS4 (aggrecanase) fluorogenic assay was performed using the WAAG-3R fluorescent substrate (Anaspec, Catalog # 60431-1 Abz-TEGEARGSVI- Dap(Dnp)-KK).
  • the assay buffer contains 5OmM HEPES (pH 7.5) 10OmM NaCl, 5mM CaCl 2 , 0.1% CHAPS, 5% Glycerol.
  • the total reaction volume is 40 ⁇ l.
  • the aggrecanase enzyme full length 68kDa supplied by GSK is used at a final concentration of 48nM.
  • the inhibitor compounds are re-suspended in 100% DMSO and then diluted with Ix assay buffer to a 10x concentration (10% DMSO).
  • the aggrecanase enzyme is incubated with various inhibitor compound concentrations, shaking, for 30 minutes at room temperature.
  • the reaction is initiated by adding the diluted WAAG-3R substrate (final concentration 25 ⁇ M).
  • the fluorescence was monitored at an excitation of 34OnM and an emission of 42OnM.
  • the reaction is run at 37 0 C and readings are taken every 30 seconds for 1 hour.
  • Activity is measured as the % inhibition using the following equation: 100*(l-(slope of enzyme + inhibitor/ slope of enzyme alone). Activities for invention compounds were measured as IC 50 values, which is the concentration of inhibitor that blocks enzyme activity to 50%
  • the compounds of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration.
  • the active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions.
  • the active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier.
  • a valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, Mack Publishing.
  • the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
  • intravenous bolus or infusion
  • intraperitoneal subcutaneous
  • intramuscular form all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.
  • An effective but nontoxic amount of the compound desired can be employed as an anti-inflammatory and anti-arthritic agent.
  • the compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
  • the daily oral dosage of each active ingredient when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 70 to 1400 mg/day.
  • the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
  • the compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches wall known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamallar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • Dosage forms suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit.
  • the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.
  • Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
  • Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of e medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. [000175] In general, water, suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are suitable stabilizing agents.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
  • Scheme 1 summarizes the preparation of the compounds of the invention.
  • the solution was diluted with dichloromethane (50 ml), which was further washed with saturated sodium bicarbonate (25 ml), water (25 ml), salt (25 ml) and dried over Mg 2 SO 4 .
  • the solvent was removed in vacuo to give tert-butyl A- (ethyl(m-tolyl)carbamoyl)benzylcarbamate.
  • the acylation product was treated with 50% TFA in dichloromethane (25 ml) at room temperature for 20 minutes.
  • the pure product can be obtained through the purification with RP-HPLC (Luna, 5 ⁇ C8(2), 100x21mm, 40-95% CH3C ⁇ /H 2 O, 0.1% TFA, 20 min). MS: calcd for C31H33C1N6O3+H + 573.24, found 573.3.
  • the pure product can be obtained through the purification with RP-HPLC (Luna, 5 ⁇ C8(2), 100x21mm, 40-95% CH 3 C ⁇ /H 2 O, 0.1% TFA, 20 min). MS: calcd for C29H29C1N6O+H + 513.22, found 513.30.
  • reaction solution was neutralized and directly purified with RP- HPLC (Luna, 5 ⁇ C8(2), 100x21mm, 4-40% CH 3 CN/H 2 O, 0.1% TFA, 19 min) to give the desired product as a TFA salt (3.5 mg, 35% yied).
  • reaction solution was acidified and directly purified with RP- ⁇ PLC (Luna, 5 ⁇ C8(2), 100x21mm, 40-95% CH 3 CN/H 2 O, 0.1% TFA, 20 min) to give the desired product as TFA salt (18.9 mg, 57%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to compounds of formula (I): that modulate, e.g., inhibit, aggrecanase proteolytic activity, which is implicated in joint diseases including osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, and rheumatoid arthritis. The current invention also relates to processes for making the compounds of the invention and to pharmaceutical compositions containing these compounds. The present invention further provides methods of treating diseases associated with aggrecanase activity, e.g., osteoarthritis and other joint diseases, using the compounds of the invention.

Description

2,4-DIAMINO-1,3,5-TRIAZINE AND 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS AGGRECANASE INHIBITORS
FIELD OF THE INVENTION
[0001] The invention is directed to compounds that inhibit aggrecanase proteolytic activity which is implicated in joint diseases including osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, rheumatoid arthritis, and other diseases and pathological conditions. The invention is also directed to processes for making the invention compounds, to pharmaceutical compositions, and to methods of treatment osteoarthritis and other joint diseases using the invention compounds.
BACKGROUND OF THE INVENTION
[0002] Osteoarthritis is characterized by progressive enzymatic destruction of type II collagen and aggrecan, which are the two major components of cartilage matrix. [0003] Type II collagen is essential for cartilage tensile strength and its degradation causes progression of osteoarthritis.
[0004] Aggrecan is composed of a core protein of approximately 2400 amino acids. The molecule consists of several structural and functional domains (Falnnery et al., Matrix Biology 16, 1998, 507-511). Three domains are defined on the N-terminal side: (1) the Gl, (2) the interglobular, and (3) the G2 domain. The aggrecan C-terminal side comprises two glycosaminoglycan rich domains. The Gl domain is separated from a second globular domain, G2, by about 150 amino acids, known as the interglobular domain. From the G2 domain to the C-terminus there is a long extended region consisting of two glycosaminoglycan-rich domains. The first is rich in keratan sulfate, whereas that which follows is rich in chondroitin sulfate. The Gl domain of aggrecan binds to long hyaluronic acid polymers, thereby forming multi molecular aggregates that effectively immobilize aggrecan within the collagen fibrillar meshwork. The glycosaminoglycan domains provide osmotic pressure, which enables cartilage to resist compression.
[0005] The loss of aggrecan contributes to the progression of osteoarthritis. In osteoarthritis and rheumatoid arthritis, aggrecan is one of the first cartilage matrix components to undergo measurable loss (Mankin et al., /. Bone Joint Surg. 52A, 424- 434 (1970)). In human arthritis in particular, aggrecan degradation is associated with amino acid cleavage within the interglobular domain, at either the Asn341-Phe342 or the GIu373- Ala374 site. In vitro studies have demonstrated that the aggrecan Asn341-Phe342 bond can be cleaved by several collagenases including collagenase- 1 and collagenase-3 (Fonsang et al., FEBS Lett. 380: 17-20, 1996a); however, digestion of aggrecan with a number of these purified proteases has not resulted in cleavage at the Glu373-Ala374 site (Fonsang et al., /. Biol. Chem. 267, 19470-19074, (1992); Flannery et al /. Biol. Chem. 267, 1008-1014 (1992)).
[0006] Current osteoarthritis therapies (e.g., non-steroidal anti-inflamatories or
"NSAIDs") have limited symptomatic benefit and have only modest, if any, effects on slowing cartilage destruction in osteoarthritic joints. NSAIDs, such as, acetaminophen, act by inhibiting the synthesis of cytokines, such as, prostaglandins that cause pain and swelling. While inhibitors of cartilage degrading enzymes will block cartilage collagen and aggrecan degradation (thereby blocking or slowing the progression of osteoarthritis), NSAIDs do not directly prevent cartilage destruction. Inhibition of aggrecanase should have a more direct and specific effect on cartilage breakdown than cytokine inhibition in the treatment of osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, and rheumatoid arthritis.
SUMMARY OF THE INVENTION
[0007] These and other needs are met by the present invention which in one aspect is directed to a compound of formula I
Figure imgf000003_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3-
C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2;
Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Ci-C6)alkyl; R1 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
C6)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra;
R3 is hydrogen or (Ci -C6) alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, Or -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
R12-N independently selected from Ra or 11 in which Rn is hydrogen or (Ci-
C6) alkyl; R12 is hydrogen, (Ci-C6) alkyl, -CO(d-C6)alkyl, -CO(C1- C6)cycloalkyl, -CO(Ci-C6)heterocycloalkyl, -CO(Ci-C6) aryl, -CO(Ci- C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and Ri2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R6 is hydrogen or (Ci -C6) alkyl; R7 and Rg are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra;
Rg is hydrogen, halo or (Ci-C6)alkyl;
R10 is hydrogen or (Ci-Ce)alkyl; or
Rg and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(Ci-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000005_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-Ce)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(d-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(CrC6)alkyl, -OC(O)NH2, -OC(O)NH(CrC6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(d-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(d-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(d-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl. In one embodiment, the invention is directed to a compound of formula II
Figure imgf000006_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R1 is optionally substituted with 1, 2 or 3 (CrC6)alkyl, (CrC6)alkoxy or (CrC6)haloalkyl or 1, 2 or 3 groups independently selected from Ra ;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Ci-Ce)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionallsy substituted with Ra;
R3 is hydrogen or (Ci-C6)alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, Or -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (Ci-C6)alkyl; R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
R12-N independently selected from Ra or 11 in which Rn is hydrogen or (Ci-
C6) alkyl; R12 is hydrogen, (Ci-C6) alkyl, -CO(Ci-C6)alkyl, -CO(Ci-
C6)cycloalkyl, -CO(Ci-C6)heterocycloalkyl, -CO(Ci-C6) aryl, -CO(Ci-
C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra;
R6 is hydrogen or (Ci -C6) alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
C6)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra;
R9 is hydrogen, halo or (Ci -C6) alkyl;
Rio is hydrogen or (Ci-C6)alkyl; or
R9 and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(Ci-C6)alkyl, and -O-(Ci-C6)alkyl, -S-(Ci-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000007_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2-C6)alkenyloxy, (Ci- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(d-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(Ci- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
[0009] In one embodiment, the invention is directed to a compound of formula
III:
Figure imgf000008_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, OR1, SR1, (CrC8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3- C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2; R1 is hydrogen, (C1-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(C1-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(C1- Ce)alkyl, heteroaryl, heteroaralkyl, (C1-Ce)carboxyalkyl, ary 1OXy(C1 -Ce)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C1- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (CrCόjalkyl; R1 is optionally substituted with 1, 2 or 3 (C1-C6)alkyl, (C1-C6)alkoxy or (CrCejhaloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (C1-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(C1-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(C1- Ce)alkyl, heteroaryl, heteroaralkyl, (C1-Ce)carboxyalkyl, ary 1OXy(C1 -Ce)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C1- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or R1 and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-C6)alkyl; m is O, I, or 2;
R4 is hydrogen or (Ci-C6)alkyl;
R6 is hydrogen or (Ci-C6)alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra; R9 is hydrogen, halo or (Ci-C6)alkyl; Rio is hydrogen or (Ci-C6)alkyl; or
R9 and Ri0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(CrC6)alkyl, and -O-(CrC6)alkyl, -S-(CrC6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000009_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl;
B t is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
Rn is hydrogen or (Ci-C6) alkyl; RJ2 is hydrogen, (Ci-C6) alkyl, -CO(Ci- C6)alkyl, -CO(Cj -C6)cycloalkyl, -CO(Ci-C6)heterocycloalkyl, -CO(Ci-C6) aryl, - CO(Ci-C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and Ri2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; at least two of three of Zi, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2-C6)alkenyloxy, (Ci- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (CrC6)alkylamino, di-[(CrC6)alkyl]amino, formyl, -C(=O)(CrC6)alkyl, -C(=N)(CrC6)alkyl, carboxy, CO2(CrC6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(d-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with RCi and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
[00010] In one embodiment, the invention is directed to a compound of formula
IV:
Figure imgf000010_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRj, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3- C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NRiR2; Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-djcarboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Ci-C6)alkyl; R1 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (CrC6)carboxyalkyl, ary 1OXy(C1 -C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C1-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Q-Cejalkyl; R2 is optionally substituted with 1, 2 or 3 (C1-C6)alkyl, (C1-C6)alkoxy or (Q-Cejlialoalkyl or 1, 2 or 3 groups independently selected from Ra; or R1 and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra;
R3 is hydrogen or (C1-Ce)alkyl; m is O, I, or 2;
X is absent, -CONR4-, Or -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (C ^C6) alkyl;
R5 is hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
R12-N independently selected from Ra or 11 in which R11 is hydrogen or (C1-
C6) alkyl; R12 is hydrogen, (C1-C6) alkyl, -CO(C1-C6)alkyl, -CO(C1- C6)cycloalkyl, -COtd-Ce^eterocycloalkyl, -CO(C1-C6) aryl, -CO(C1- C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R11 and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R6 is hydrogen or (Ci-C6)alkyl; n is 0, 1, 2 or 3; R7 and Rg are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci- Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or 3 groups independently selected from Ra;
Figure imgf000012_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (CrC6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(C1-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(Ci-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-Ce)alkyl, amino, cyano, nitro, or hydroxyl.
[00011] In another embodiment, the invention is directed to a compound of any of formulae I-IV, wherein the compound is selected from:
Figure imgf000012_0002
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
-20-
Figure imgf000022_0001
or a pharmaceutically acceptable salt thereof. [00012] In another aspect, the invention is directed to a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I- IV, or a pharmaceutically acceptable salt thereof.
[00013] In another aspect, the invention is directed to a method for treating or preventing an inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof. [00014] In another aspect, the invention is directed to a method of treating a condition or disease mediated by aggrecanase, e.g., osteoarthritis, in a mammalian subject. The method comprises administering to the subject a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof.
[00015] In another aspect, the invention is directed to a method of treating a subject suffering from osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis, or rheumatoid arthritis, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein, e.g., a compound of formulae I-IV, or a pharmaceutically acceptable salt thereof. [00016] In another aspect, the invention is directed to a process for making a compound disclosed herein, e.g., a compound of formulae I-IV, comprising the steps outlined in Schemes 1-8 infra.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[00017] In order to more clearly and concisely describe the subject matter of the claims, the following definitions are intended to provide guidance as to the meaning of specific terms used herein.
[00018] It is to be noted that the singular forms "a," "an," and "the" as used herein include "at least one" and "one or more" unless stated otherwise. Thus, for example, reference to "a pharmacologically acceptable carrier" includes mixtures of two or more carriers as well as a single carrier, and the like.
[00019] "Halogen" means fluoro, chloro, iodo, and bromo. [00020] "Alkyl" includes both straight and branched chain alkyl groups. (Ci-
Ce)alkyl means an alkyl group having 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t- pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.
[00021] The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
[00022] "Cycloalkyl" means a partially or fully saturated ring ring system. "(C3-
C7)cycloalkyl" means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
[00023] "Heterocycloalkyl" means a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s).
Heterocycle may be saturated or partially unsaturated and may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween.
[00024] "(Ci-C6)AIkOXy", "(C2-C6)alkennyloxy", and "(C2-C6)alkynyloxy" refer to alkyl, alkenyl, and alkynyl groups as defined above that are attached to O. Examples include methoxy, ethoxy, vinyloxy, allyloxy, ethynyloxyy, and 2-propynyloxy.
[00025] "(Ci-C6)Alkylthio" means an alkyl group attached to S. Examples include methylthio, ethylthio and propylthio.
[00026] "(Ci-C6)Alkylsulfinyl" means an alkyl group attached to SO. Examples include methylsulphinyl and ethylsulphinyl.
[00027] "(Ci-C6)Alkylsulfonyl" means an alkyl group attached to SO . Examples include methylsulfonyl and ethylsulfonyl. [00028] "Amino" means NH .
[00029] "(Ci-C6)Alkylamino" means (CrC6)alkyl-NH. Examples include methylamino, ethylamino, propylamino, isopropylamino and butylamino.
[00030] "((Ci-C6)Alkyl) amino" means ((Ci-C6)alkyl) -N. Examples include dimethylamino, diethylamino, N-ethyl- N-methylamino and diisopropylamino. [00031] "Formyl" means C(=O)-H.
[00032] "(C2-C6)alkanoyl" means C(=O)-( d-C6)alkyl. Examples include acetyl and propionyl. [00033] "Carboxy" means CO H.
[00034] "(Ci-C6)Alkoxycarbonyl" means CO (d-C6)alkyl. Examples include methoxycarbonyl, ethoxycarbonyl, propoxy- carbonyl and tert-butoxycarbonyl. [00035] "(Ci-C6)Alkanoyloxy" means O-C(=O)-(Ci-C6)alkyl. Examples include acetoxy and propionyloxy. [00036] "Carbamoyl" means C(=O)NH .
[00037] "N-(Ci -C6)alkyl-carbamoyl" means C(=O)NH(Ci-C6)alkyl. Examples include N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl.
[00038] "N-((Ci-C6)alkyl) -carbamoyl" means C(=O)N(Ci-C6)alkyl) . Examples include N,N- dimethylcarbamoyl, and N,N-diethylcarbamoyl.
[00039] "(C2-C6)Alkanoylamino" means N-C(=O)-(CrC6)alkyl. Examples include acetamido and propionamido.
[00040] "N-(Ci -C6)alkyl)( C2-C6)Alkanoylamino" means N(d-C6)alkyl-C(=O)-
(Ci-C6)alkyl). Examples include N-methylacetamido and N-methylpropionamido.
[00041] "Carbamimidoyl" means C(=O)NH2.
[00042] "Ureido" means -NH-C(O)NH2.
[00043] "Sulfamoyl" means SO -NH2.
[00044] "N-(Ci -C6)alkylsulfamoyl" means SO2-NH(Ci-C6)alkyl. Examples include N-methylsulfamoyl and N-ethyl-sulphamoyl.
[00045] "N,N-di-(Ci-C6)alkylsulfamoyl" means SO2-N((Ci-C6)alkyl)2. Examples include N,N, dimethylsulfamoyl.
[00046] "(Ci-C6)alkylsulfonylamino" means -NH-SO2-(CrC6)alkyl.
[00047] "Arylsulfonylamino" means -NH-SO2-aryl.
[00048] "Aryl" means an optionally substituted monocyclic or bicyclic ring system containing at least one aromatic ring. Examples and suitable values of the term
"aryl" are phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indyl and indenyl.
[00049] "Heteroaryl" means an optionally substituted monocyclic or bicyclic ring systemcontaining at least one aromatic ring and at least one heteroatom selected independently from N, O or S. Examples of "heteroaryl" include thiophene, thienyl, pyridyl, thiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl and thiadiazolyl, benzoimidazolyl, benzooxazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, indolyl, isoindolyl, pyridonyl, pyridazinyl, pyrimidinyl, imidazopyridyl, oxazolopyridyl, thiazolopyridyl, pyridyl, imidazopyridazinyl, oxazolopyridazinyl, thiazolopyridazinyl and purinyl. [00050] "Aralkyl", "heteroaralkyl", and "cycloalkylalkyl" refer to a substituent that is attached via the alkyl group to an aryl, heteroaryl or cycloalkyl group. [00051] Unless otherwise stated, a "5- or 6-membered ring" refers to aromatic and heteroaromatic rings, as well as carbocyclic and heterocyclic rings, which may be partially or fully saturated. Examples of such rings include, but are not limited to furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl, cyclopentyl and cyclohexenyl.
[00052] As used herein, the phrase "pharmaceutically acceptable salts" means derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from nontoxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, trifluoroacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
[00053] The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
[00054] The compounds described herein may have asymmetric centers.
Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like, can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
[00055] The term "substituted", as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the normal valency of the designated atom is not exceeded, and that the substitution results in a stable compound. When the substituted group is C=O, then 2 hydrogens on the carbon atom in question have been replaced.
[00056] When any variable such as n, x, R', or Ra occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R6 (that is, when n= 0, 1, or 2) then that group may optionally be substituted with up to two R6 groups and R6 at each occurrence is selected independently from the definition of R6. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. [00057] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then that substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then that substituent may be bonded via any atom of that substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. [00058] "Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to modulate, e.g., inhibit, aggrecanase activity in a subject. A therapeutically effective amount of a compound of the invention, as defined herein, may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound are outweighed by the therapeutically beneficial effects.
[00059] A therapeutically effective amount of a compound of the invention (i.e., an effective dosage) may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0. 1 to 30 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present, if any. Moreover, treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound of the invention in the range of between about 0.1 and 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.
Compounds of the Invention
[00060] In some aspects, the present invention is directed to compounds of formula I:
Figure imgf000028_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3-
C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2;
Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3-
C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci-
Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-
Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3,
4, 5, or 6-membered saturated or partially unsaturated ring optionally containing
0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (CrC6)alkyl, (CrC6)alkoxy or (CrC6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle with 1, 2 or 3 heteroatoms and optionally substituted with Ra;
R3 is hydrogen or (Ci-C6)alkyl; m is O, 1, or 2;
X is absent, -CONR4- -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups R12-N independently selected from Ra or 11 in which R11 is hydrogen or (C1-
C6) alkyl; R12 is hydrogen, (C1-C6) alkyl, -CO(CrC6)alkyl, -CO(C1-
C6)cycloalkyl, -CO(CrC6)heterocycloalkyl, -CO(C1-C6) aryl, -CO(C1-
C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R11 and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2, or 3 heteroatoms and optionally substituted with Ra;
R6 is hydrogen or (C1 -C6) alkyl;
R7 and R8 are each independently hydrogen, halogen, (C1-C6)alkyl or (C1-
C6)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra;
R9 is hydrogen, halo or (C1 -C6) alkyl;
R1O is hydrogen or (Q-C^alkyl; or
R9 and R10 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(CrC6)alkyl, and -O-(CrC6)alkyl, -S-(CrC6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000030_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Q-C^alkyl, or (Q-C^alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (d-QOalkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (Ci-C6)alkylthio, (Q-C^alkylsulfinyl, (Q-QOalkylsulfonyl, amino, (CrC^alkylamino, di-IXCrCfOalkylJamino, formyl, -C(=O)(C1-C6)alkyl, -C(=N)(d-C6)alkyl, carboxy, CO2(C!-C6)alkyl, CONH2, -Q=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(C1-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((Cr C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -0C(0)NH(Ci-C6)alkyl, - OC(O)NH((C!-C6)alkyl)2, -NHC(O)(d-C6)alkyl, -N(C1-C6)alkyl-C(O)(C1- C6)alkyl, -NH-C(O)NH2, -N(Ci-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (Ci- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc; and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
[00061] In some embodiments, Y is selected from the group consisting of H, halo,
ORi, (Ci-C8)alkyl, and NRiR2. In some embodiments, Y is H. In some embodiments, Y is Cl. In some embodiments, Y is OH. In some embodiments, Y is OMe. In some embodiments, Y is -NRiR2, e.g., a compound of formula II. [00062] In some embodiments, Ri is selected from the group consisting of hydrogen and (Ci-C6)alkyl. In some embodiments, R3 is hydrogen. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl. [00063] In some embodiments, R4 is hydrogen. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is propyl. [00064] In some embodiments, R5 is methyl. In some embodiments, R5 is ethyl. In
Me^ "I some embodiments, R5 is phenyl. In some embodiments, R5 is \ wherein
"— " indicates the point of attachment. In some embodiments, R5 is aryl optionally
substituted with 1 group selected from Ra or
Figure imgf000031_0001
. In some embodiments, -X-R5 is -SO2CH3. In some embodiments, -X-R5 is -COOH. In some embodiments, -X-R5 is
-C(CH3)3.
[00065] In some embodiments, Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, Ri2 is hydrogen. In some embodiments, Ri2 is methyl.
In some embodiments, Ri2 is heteroaryl optionally substituted with 1 group selected from Ra. In some embodiments, Ri2 is thiadiazole optionally substituted with 1 group selected from Ra. In some embodiments, Ri2 is-COCH3.
[00066] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. [00067] In some embodiments, R6 is methyl. In some embodiments, R6 is fluoro.
In some embodiments, R6 is chloro. In some embodiments, R6 is hydrogen.
[00068] In some embodiments, R7 is hydrogen. In some embodiments, R7 is methoxy. In some embodiments, R7 is methyl. In some embodiments, R7 is halogen. In some embodiments, R7 is chloro.
[00069] In some embodiments, Rg is hydrogen. In some embodiments, Rg is methoxy. In some embodiments, R8 is methyl. In some embodiments, R8 is halogen. In some embodiments, R8 is chloro.
[00070] In some embodiments, Rg is hydrogen. In some embodiments, Rg is methyl. In some embodiments, R10 is hydrogen. In some embodiments, R10 is methyl.
In some embodiments, Rg and Rio are taken together to form a 5-6 membered ring.
[00071] In some embodiments,
Figure imgf000032_0001
is phenyl. In some embodiments, is
pyridyl. In some embodiments,
Figure imgf000032_0002
is cyclohexyl.
[00072] In some embodiments,
Figure imgf000032_0003
i -s In some embodiments, M^v,
Figure imgf000032_0004
is
Figure imgf000032_0005
. In some embodiments, Z1 is N. In some embodiments, Z2 is N. In some embodiments, Z3 is N. In some embodiments, each Of Z1, Z2 and Z3 are independently N. [00073] In some embodiments, X is -SO2-. In some embodiments, X is -CONR4-
. In some embodiments, X is -COO-. In some embodiments, X is -SO2NR4- [00074] In some embodiments, Ra is fluoro. In some embodiments, Ra is chloro.
In some embodiments, Ra is methyl. In some embodiments, Ra is ethyl. In some embodiments, Ra is trifluoromethyl. In some embodiments, Ra is methoxy. In some embodiments, Ra is ethoxy. In some embodiments, Ra is trifluoromethoxy. In some embodiments, Ra is cyano. In some embodiments, Ra is nitro. In some embodiments, Ra is hydroxyl. In some embodiments, Ra is amino. In some embodiments, Ra is -NHCH3. In some embodiments, Ra is -N(CH3)2. In some embodiments, Ra is phenyl. In some embodiments, Ra is pyridyl. In some embodiments, Ra is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, Ra is vinyl, propenyl, or butenyl. In some embodiments, Ra is acetylenyl, propynyl or butynyl. In some embodiments, Ra is methylthio. In some embodiments, Ra is methylsulfinyl. In some embodiments, Ra is methylsulfonyl. In some embodiments, Ra is formyl. In some embodiments, Ra is - C(=O)CH3. In some embodiments, Ra is -C(=N)CH3. In some embodiments, Ra is carboxy. In some embodiments, Ra is CO2CH3. In some embodiments, Ra is CONH2. In some embodiments, Ra is -C(=N)NH2. In some embodiments, Ra is -C(=N)NH(CH3). In some embodiments, Ra is -CC=N)N(CH3) . In some embodiments, Ra is CONH(CHs).
In some embodiments, Ra is CON(CH3)2. In some embodiments, Ra is OC(O)(CH3). In some embodiments, Ra is -OC(O)NH2. In some embodiments, Ra is -OC(O)NH(CH3). [00075] In some embodiments, Rc is chloro. In some embodiments, Rc is fluoro.
In some embodiments, Rc is methyl. In some embodiments, Rc is trifluoromethyl. In some embodiments, Rc is trifluoromethoxy. In some embodiments, Rc is cyano. In some embodiments, Rc is nitro. In some embodiments, Rc is hydroxyl. [00076] In one embodiment, the compounds of the invention are compounds of formula IA
Figure imgf000033_0001
or pharmaceutically acceptable salts thereof.
[00077] In one embodiment, the compounds of the invention are compounds of formula IA-i
Figure imgf000033_0002
or pharmaceutically acceptable salts thereof. [00078] In another embodiment, the compounds of the invention are compounds of formula IB
Figure imgf000034_0001
or pharmaceutically acceptable salts thereof.
[00079] In another embodiment, compounds of the invention are compounds of formula IC
Figure imgf000034_0002
or pharmaceutically acceptable salts thereof.
[00080] In yet another embodiment, compounds of the invention are compounds of formula ID
Figure imgf000034_0003
or pharmaceutically acceptable salts thereof.
[00081] In a further embodiment, compounds of the invention are compounds of formula IE
Figure imgf000034_0004
or pharmaceutically acceptable salts thereof. [00082] In another embodiment, compounds of the invention are compounds of formula IF
Figure imgf000035_0001
or pharmaceutically acceptable salts thereof.
[00083] In yet another embodiment, compounds of the invention are compounds of formula IG
Figure imgf000035_0002
or pharmaceutically acceptable salts thereof.
[00084] In another embodiment, compounds of the invention are compounds of formula IH
Figure imgf000035_0003
or pharmaceutically acceptable salts thereof.
[00085] In a further embodiment, compounds of the invention are compounds of formula IJ
Figure imgf000035_0004
or pharmaceutically acceptable salts thereof. [00086] In a further embodiment, compounds of the invention are compounds of formula IJ-i
Figure imgf000036_0001
or pharmaceutically acceptable salts thereof.
[00087] In another embodiment, compounds of the invention are compounds of formula IK
Figure imgf000036_0002
or pharmaceutically acceptable salts thereof.
[00088] In another embodiment, compounds of the invention are compounds of formula IK-i
Figure imgf000036_0003
or pharmaceutically acceptable salts thereof.
[00089] In another embodiment, compounds of the invention are compounds of formula IK-ii
Figure imgf000036_0004
or pharmaceutically acceptable salts thereof. [00090] In another embodiment, compounds of the invention are compounds of formula IK-iii
Figure imgf000037_0001
or pharmaceutically acceptable salts thereof.
[00091] In yet another embodiment, compounds of the invention are compounds of formula IL
Figure imgf000037_0002
or pharmaceutically acceptable salts thereof.
[00092] In yet another embodiment, compounds of the invention are compounds of formula IL-i
Figure imgf000037_0003
or pharmaceutically acceptable salts thereof.
[00093] In another embodiment, compounds of the invention are compounds of formula IM
Figure imgf000037_0004
or pharmaceutically acceptable salts thereof.
[00094] In another embodiment, compounds of the invention are compounds of formula IM-i
Figure imgf000038_0001
or pharmaceutically acceptable salts thereof.
[00095] In one embodiment, the compounds of the invention are compounds of formula IN
Figure imgf000038_0002
or pharmaceutically acceptable salts thereof.
[00096] In another embodiment, the compounds of the invention are compounds of formula IO
Figure imgf000038_0003
or pharmaceutically acceptable salts thereof.
[00097] In another embodiment, compounds of the invention are compounds of formula IP
Figure imgf000038_0004
pharmaceutically acceptable salts thereof. [00098] In one embodiment, the compounds of the invention are compounds of formula IQ
Figure imgf000039_0001
or pharmaceutically acceptable salts thereof. In some embodiments R5 is hydrogen. In some embodiments, R5 is methyl.
[00099] In another embodiment, the compounds of the invention are compounds of formula IR
Figure imgf000039_0002
or pharmaceutically acceptable salts thereof. In some embodiments R5 is hydrogen. In some embodiments, R5 is methyl.
[000100] The substituents and embodiments disclosed for the compounds of formulae IA-IR are the same as those disclosed herein for compounds of formula I. [000101] In one embodiment, the invention is directed to a compound of formula II
Figure imgf000039_0003
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-C6)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (C1- C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle with having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-C6)alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, Or -SO2-, -SO2NR4-, or -COO-; R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
O
R12-N independently selected from Ra or 11 in which R11 is hydrogen or (C1-
C6) alkyl; R12 is hydrogen, (C1-C6) alkyl, -CO(C1-C6)alkyl, -CO(C1- C6)cycloalkyl, -COtQ-Cejlieterocycloalkyl, -CO(C1-C6) aryl, -CO(C1- C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R11 and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R6 is hydrogen or (C ^C6) alkyl; R7 and Rg are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra;
Rg is hydrogen, halo or (Ci-C6)alkyl;
R10 is hydrogen or (Ci-Ce)alkyl; or
Rg and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(Ci-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000041_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-Ce)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(d-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(CrC6)alkyl, -OC(O)NH2, -OC(O)NH(CrC6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(d-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(d-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(d-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
[000102] In some embodiments, Ri is selected from the group consisting of hydrogen and (Ci-C6)alkyl. In some embodiments, Ri is hydrogen. In some embodiments, Ri is methyl. In some embodiments, Ri is ethyl. [000103] In some embodiments, R2 is methyl. In some embodiments, R2 is isopropyl. In some embodiments, R2 is cyclohexyl. In some embodiments, R2 is benzyl.
Figure imgf000042_0001
In some embodiments, R2 is phenyl. In some embodiments, R2 is wherein "— " indicates the point of attachment. In some embodiments, R2 is
wherein "— " indicates the point of attachment. In some embodiments, R2
Figure imgf000042_0002
is ' , wherein "— " indicates the point of attachment. In some embodiments,
R2 is
Figure imgf000042_0003
, wherein "— " indicates the point of attachment.
[000104] In some embodiments, R3 is hydrogen. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl.
[000105] In some embodiments, R4 is hydrogen. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is propyl. [000106] In some embodiments, R5 is methyl. In some embodiments, R5 is ethyl.
---"^
In some embodiments, R5 is phenyl. In some embodiments, R5 is wherein "— " indicates the point of attachment. In some embodiments, R5 is aryl
O
R12-N optionally substituted with 1 group selected from Ra or 11 . In some embodiments, -X-R5 is -SO2CH3. In some embodiments, -X-R5 is -COOH. In some embodiments, -X-R5 is -C(CH3)3.
[000107] In some embodiments, Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, R12 is hydrogen. In some embodiments, R12 is methyl. In some embodiments, R12 is heteroaryl optionally substituted with 1 group selected from Ra. In some embodiments, R12 is thiadiazole optionally substituted with 1 group selected from Ra.
[000108] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
[000109] In some embodiments, R6 is methyl. In some embodiments, R6 is fluoro.
In some embodiments, R6 is chloro. In some embodiments, R6 is hydrogen.
[000110] In some embodiments, R7 is hydrogen. In some embodiments, R7 is methoxy. In some embodiments, R7 is methyl. In some embodiments, R7 is halogen. In some embodiments, R7 is chloro.
[000111] In some embodiments, R is hydrogen. In some embodiments, R is
8 8 methoxy. In some embodiments, R is methyl. In some embodiments, R is halogen. In
8 8 some embodiments, R is chloro.
[000112] In some embodiments, R9 is hydrogen. In some embodiments, R9 is methyl. In some embodiments, Rio is hydrogen. In some embodiments, Rio is methyl. In some embodiments, R9 and Ri0 are taken together to form a 5-6 membered ring.
[000113] In some embodiments,
Figure imgf000043_0001
is phenyl. In some embodiments, is
pyridyl. In some embodiments,
Figure imgf000043_0002
is cyclohexyl.
[000114] In some embodiments,
Figure imgf000043_0003
I iSs N . IInn : some embodiments,
Z32 is N In some embodiments, Z32 is \s^ . In some embodiments, Zi is N. In some embodiments, Z2 is N. In some embodiments, Z3 is N. In some embodiments, each of Zi, Z2 and Z3 are independently N. [000115] In some embodiments, X is -SO2-. In some embodiments, X is -CONR4- . In some embodiments, X is -COO-. In some embodiments, X is -SO2NR4-. [000116] In some embodiments, Ra is fluoro. In some embodiments, Ra is chloro. In some embodiments, Ra is methyl. In some embodiments, Ra is ethyl. In some embodiments, Ra is trifluoromethyl. In some embodiments, Ra is methoxy. In some embodiments, Ra is ethoxy. In some embodiments, Ra is trifluoromethoxy. In some embodiments, Ra is cyano. In some embodiments, Ra is nitro. In some embodiments, Ra is hydroxyl. In some embodiments, Ra is amino. In some embodiments, Ra is -NHCH3. In some embodiments, Ra is -N(CH3)2. In some embodiments, Ra is phenyl. In some embodiments, Ra is pyridyl. In some embodiments, Ra is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, Ra is vinyl, propenyl, or butenyl. In some embodiments, Ra is acetylenyl, propynyl or butynyl. In some embodiments, Ra is methylthio. In some embodiments, Ra is methylsulfinyl. In some embodiments, Ra is methylsulfonyl. In some embodiments, Ra is formyl. In some embodiments, Ra is - CC=O)CH3. In some embodiments, Ra is -C(=N)CH3. In some embodiments, Ra is carboxy. In some embodiments, Ra is CO2CH3. In some embodiments, Ra is CONH2. In some embodiments, Ra is -C(=N)NH2. In some embodiments, Ra is -C(=N)NH(CH3). In some embodiments, Ra is -C(=N)N(CH3) . In some embodiments, Ra is CONH(CH3). In some embodiments, Ra is CON(CH3)2. In some embodiments, Ra is OC(O)(CH3). In some embodiments, Ra is -OC(O)NH2. In some embodiments, Ra is -OC(O)NH(CH3). [000117] In some embodiments, Rc is chloro. In some embodiments, Rc is fluoro. In some embodiments, Rc is methyl. In some embodiments, Rc is trifluoromethyl. In some embodiments, Rc is trifluoromethoxy. In some embodiments, Rc is cyano. In some embodiments, Rc is nitro. In some embodiments, Rc is hydroxyl. [000118] In one embodiment, compounds of the invention are compounds of formula HA
Figure imgf000044_0001
or pharmaceutically acceptable salts thereof.
[000119] In another embodiment, compounds of the invention are compounds of formula HB
Figure imgf000045_0001
or pharmaceutically acceptable salts thereof.
[000120] In yet another embodiment, compounds of the invention are compounds of formula HC
Figure imgf000045_0002
or pharmaceutically acceptable salts thereof.
[000121] In a further embodiment, compounds of the invention are compounds of formula HD
Figure imgf000045_0003
or pharmaceutically acceptable salts thereof.
[000122] In another embodiment, compounds of the invention are compounds of formula HE
Figure imgf000045_0004
or pharmaceutically acceptable salts thereof.
[000123] In another embodiment, compounds of the invention are compounds of formula HF
Figure imgf000046_0001
or pharmaceutically acceptable salts thereof.
[000124] In yet another embodiment, compounds of the invention are compounds of formula HG
Figure imgf000046_0002
or pharmaceutically acceptable salts thereof.
[000125] In another embodiment, compounds of the invention are compounds of formula IIH
Figure imgf000046_0003
or pharmaceutically acceptable salts thereof.
[000126] In another embodiment, compounds of the invention are compounds of formula IU
Figure imgf000047_0001
or pharmaceutically acceptable salts thereof.
[000127] In yet another embodiment, compounds of the invention are compounds of formula HK
Figure imgf000047_0002
or pharmaceutically acceptable salts thereof.
[000128] In another embodiment, compounds of the invention are compounds of formula HL
Figure imgf000047_0003
or pharmaceutically acceptable salts thereof.
[000129] In a further embodiment, compounds of the invention are compounds of formula IIM
Figure imgf000047_0004
or pharmaceutically acceptable salts thereof. [000130] In another embodiment, compounds of the invention are compounds of formula UN
Figure imgf000048_0001
or pharmaceutically acceptable salts thereof.
[000131] The substituents and embodiments disclosed for the compounds of formulae IIA-IIN are the same as those disclosed herein for compounds of formula II.
[000132] In one embodiment, the invention is directed to a compound of formula
III:
Figure imgf000048_0002
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3- C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2; Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (CrC6)alkyl, (CrC6)alkoxy or (CrC6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-C6)alkyl; m is O, I, or 2;
R4 is hydrogen or (Ci -C6) alkyl;
R6 is hydrogen or (Ci-C6)alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra; R9 is hydrogen, halo or (Ci -C6) alkyl; Rio is hydrogen or (Ci-C6)alkyl; or
R9 and Ri0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(Ci-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000049_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl;
B is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
Rn is hydrogen or (Ci-C6) alkyl; RJ2 is hydrogen, (Ci-C6) alkyl, -CO(Ci- C6)alkyl, -CO(Cj -C6)cycloalkyl, -CO(Ci-C6)heterocycloalkyl, -CO(Ci-C6) aryl, - CO(Ci-C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (CrC6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (CrC6)alkylthio, (CrC6)alkylsulfinyl, (CrC6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(Ci-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc; and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
[000133] In some embodiments, Y is selected from the group consisting of H, halo, OR1, (CrC8)alkyl, and NR1R2. In some embodiments, Y is H. In some embodiments, Y is Cl. In some embodiments, Y is OH. In some embodiments, Y is OMe. In some embodiments, Y is -NRiR2.
[000134] In some embodiments, R1 is selected from the group consisting of hydrogen and (Ci-C6)alkyl. In some embodiments, Ri is hydrogen. In some embodiments, Ri is methyl. In some embodiments, Ri is ethyl. [000135] In some embodiments, R2 is methyl. In some embodiments, R2 is isopropyl. In some embodiments, R2 is cyclohexyl. In some embodiments, R2 is benzyl.
Figure imgf000050_0001
In some embodiments, R2 is phenyl. In some embodiments, R2 is wherein "— " indicates the point of attachment. In some embodiments, R2 is
wherein "— " indicates the point of attachment. In some embodiments, R2
Figure imgf000051_0001
, wherein "— " indicates the point of attachment. In some embodiments,
M I e
H Me" ^i
R2 is ' , wherein "— " indicates the point of attachment.
[000136] In some embodiments, R3 is hydrogen. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl.
[000137] In some embodiments, R4 is hydrogen. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is propyl.
[000138] In some embodiments, Rn is hydrogen. In some embodiments, Rn is methyl. In some embodiments, Ri2 is hydrogen. In some embodiments, Ri2 is methyl.
In some embodiments, R12 is heteroaryl optionally substituted with 1 group selected from Ra. In some embodiments, Ri2 is thiadiazole optionally substituted with 1 group selected from Ra. In some embodiments, R12 is -COCH3.
[000139] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
[000140] In some embodiments, R6 is methyl. In some embodiments, R6 is fluoro.
In some embodiments, R6 is chloro. In some embodiments, R6 is hydrogen.
[000141] In some embodiments, R7 is hydrogen. In some embodiments, R7 is methoxy. In some embodiments, R7 is methyl. In some embodiments, R7 is halogen. In some embodiments, R7 is chloro.
[000142] In some embodiments, R8 is hydrogen. In some embodiments, R8 is methoxy. In some embodiments, R8 is methyl. In some embodiments, R8 is halogen. In some embodiments, R8 is chloro. [000143] In some embodiments, Rg is hydrogen. In some embodiments, Rg is methyl. In some embodiments, R10 is hydrogen. In some embodiments, R10 is methyl. In some embodiments, R9 and R10 are taken together to form a 5-6 membered ring.
[000144] In some embodiments,
Figure imgf000052_0001
is phenyl. In some embodiments, is
pyridyl. In some embodiments,
Figure imgf000052_0002
is cyclohexyl. In some embodiments, is
phenyl. In some embodiments, — is pyridyl. In some embodiments, — is cyclohexyl.
[000145] In some embodiments,
Figure imgf000052_0003
is IInn : some embodiments,
Z32 is N In some embodiments, Z32 is \s^ . In some embodiments, Zi is N. In some embodiments, Z2 is N. In some embodiments, Z3 is N. In some embodiments, each Of Z1, Z2 and Z3 are independently N. [000146] In some embodiments, X is -SO2-. In some embodiments, X is -CONR4- . In some embodiments, X is -COO-.
[000147] In some embodiments, Ra is fluoro. In some embodiments, Ra is chloro. In some embodiments, Ra is methyl. In some embodiments, Ra is ethyl. In some embodiments, Ra is trifluoromethyl. In some embodiments, Ra is methoxy. In some embodiments, Ra is ethoxy. In some embodiments, Ra is trifluoromethoxy. In some embodiments, Ra is cyano. In some embodiments, Ra is nitro. In some embodiments, Ra is hydroxyl. In some embodiments, Ra is amino. In some embodiments, Ra is -NHCH3. In some embodiments, Ra is -N(CHs)2. In some embodiments, Ra is phenyl. In some embodiments, Ra is pyridyl. In some embodiments, Ra is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, Ra is vinyl, propenyl, or butenyl. In some embodiments, Ra is acetylenyl, propynyl or butynyl. In some embodiments, Ra is methylthio. In some embodiments, Ra is methylsulfinyl. In some embodiments, Ra is methylsulfonyl. In some embodiments, Ra is formyl. In some embodiments, Ra is - C(=O)CH3. In some embodiments, Ra is -C(=N)CH3. In some embodiments, Ra is carboxy. In some embodiments, Ra is CO2CH3. In some embodiments, Ra is CONH2. In some embodiments, Ra is -C(=N)NH2. In some embodiments, Ra is -C(=N)NH(CH3). In some embodiments, Ra is -C(=N)N(CH3)2. In some embodiments, Ra is CONH(CHs). In some embodiments, Ra is CON(CH3)2. In some embodiments, Ra is OC(O)(CH3). In some embodiments, Ra is -OC(O)NH2. In some embodiments, Ra is -OC(O)NH(CH3). [000148] In some embodiments, Rc is chloro. In some embodiments, Rc is fluoro. In some embodiments, Rc is methyl. In some embodiments, Rc is trifluoromethyl. In some embodiments, Rc is trifluoromethoxy. In some embodiments, Rc is cyano. In some embodiments, Rc is nitro. In some embodiments, Rc is hydroxyl. [000149] In one embodiment, compounds of the invention are compounds of formula IIIA
Figure imgf000053_0001
or pharmaceutically acceptable salts thereof.
[000150] In one embodiment, compounds of the invention are compounds of formula IIIB
Figure imgf000053_0002
or pharmaceutically acceptable salts thereof.
[000151] In another embodiment, compounds of the invention are compounds of formula IIIC
Figure imgf000053_0003
or pharmaceutically acceptable salts thereof.
[000152] In another embodiment, compounds of the invention are compounds of formula HID
Figure imgf000054_0001
or pharmaceutically acceptable salts thereof.
[000153] In another embodiment, compounds of the invention are compounds of formula HIE
Figure imgf000054_0002
or pharmaceutically acceptable salts thereof.
[000154] In another embodiment, compounds of the invention are compounds of formula IIIF
Figure imgf000054_0003
or pharmaceutically acceptable salts thereof.
[000155] In another embodiment, compounds of the invention are compounds of formula IIIG
Figure imgf000055_0001
or pharmaceutically acceptable salts thereof.
[000156] The substituents and embodiments disclosed for the compounds of formulae IIIA-IIIG are the same as those disclosed herein for compounds of formula III.
[000157] In one embodiment, the invention is directed to a compound of formula
IV
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3- C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2; Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R'", wherein R'" is hydrogen or (Ci-Ce)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (CrC6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or R1 and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-C6)alkyl; m is O, I, or 2;
X is absent, -CONR4-, Or -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups
R12-N independently selected from Ra or 11 in which R11 is hydrogen or (C1-
C6) alkyl; R12 is hydrogen, (C1-C6) alkyl, -CO(C1-C6)alkyl, -CO(C1- C6)cycloalkyl,
Figure imgf000056_0001
-CO(C1-C6) aryl, -CO(C1- C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R11 and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R6 is hydrogen or (Ci-C6)alkyl; n is 0, 1, 2 or 3;
R7 and Rg are each independently hydrogen, halogen, (C1-C6)alkyl or (C1- C6)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra;
Figure imgf000056_0002
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (CrCόjalkyl, or (CrCβjalkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (C1-C6)alkyl-NH, ((C1-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (Ci-C6)alkylthio, (Ci-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(d-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -Q=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, CON((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(CrC6)alkyl-C(O)NH2, N(C1-C6)alkyl-C(O)NH(C1- C6)alkyl, N(C1-C6)alkyl-C(O)NH(C1-C6)alkyl)2, -NH-C(O)NH(CrC6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with RCi and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-Ce)alkyl, amino, cyano, nitro, or hydroxyl.
[000158] In another embodiment, the invention is directed to a compound of any of formulae I-III , wherein the compound is selected from:
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
-65-
Figure imgf000067_0001
or a pharmaceutically acceptable salt thereof. [000159] Biological Activity
[000160] ADAM TS4 Fluorogenic Assay The biological activity of exemplary compounds disclosed herein was measured using an assay as disclosed in Zhang, Y. et al (2004) Journal of Pharm. And Exp. Therapeutics 309(1): 348-355, the entire contents of which are incorporated herein by reference.
[000161] The ADAM TS4 (aggrecanase) fluorogenic assay was performed using the WAAG-3R fluorescent substrate (Anaspec, Catalog # 60431-1 Abz-TEGEARGSVI- Dap(Dnp)-KK). The assay buffer contains 5OmM HEPES (pH 7.5) 10OmM NaCl, 5mM CaCl2, 0.1% CHAPS, 5% Glycerol. The total reaction volume is 40μl. The aggrecanase enzyme (full length 68kDa supplied by GSK) is used at a final concentration of 48nM. The inhibitor compounds are re-suspended in 100% DMSO and then diluted with Ix assay buffer to a 10x concentration (10% DMSO). The aggrecanase enzyme is incubated with various inhibitor compound concentrations, shaking, for 30 minutes at room temperature. The reaction is initiated by adding the diluted WAAG-3R substrate (final concentration 25 μM). The fluorescence was monitored at an excitation of 34OnM and an emission of 42OnM. The reaction is run at 370C and readings are taken every 30 seconds for 1 hour. Activity is measured as the % inhibition using the following equation: 100*(l-(slope of enzyme + inhibitor/ slope of enzyme alone). Activities for invention compounds were measured as IC50 values, which is the concentration of inhibitor that blocks enzyme activity to 50%
[000162] The compounds described herein had IC50 values of 100 μM or less. For example:
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
-76-
Figure imgf000078_0001
Figure imgf000079_0001
* = IC50of0.001- 0.050 μM ** = IC50 of 0.051- 0.200 μM *** = IC50 of 0.201-0.500 μM **** = IC50 of 0.501-1.000 μM ***** = IC50 of 1.001-5.000 μM ****** = IC50 of 5.001-100.000 μM Pharmaceutical Formulations
[000163] The compounds of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, Mack Publishing. [000164] The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but nontoxic amount of the compound desired can be employed as an anti-inflammatory and anti-arthritic agent.
[000165] The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
[000166] The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition. [000167] By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 70 to 1400 mg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily. [000168] The compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches wall known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
[000169] In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
[000170] For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
[000171] The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamallar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines. [000172] Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
[000173] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. [000174] Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of e medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. [000175] In general, water, suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Methods of Making Invention Compounds and Examples
Scheme 1 summarizes the preparation of the compounds of the invention.
Scheme 1
Figure imgf000083_0001
Preparation of 4-(aminomethyl)-Λ^-ethyl-Λ^-rø-tolylbenzamide
Figure imgf000083_0002
[000176] A solution of 4-(Boc-aminomethyl)benzoic acid (1.0 g, 3.98 mmol, 1 equivalent), N-ethyl m-toluidine (614 mg, 4.54 mmol, 1.14 equivalents) and DMAP (98 mg, 0.80 mmol, 0.2 equivalent) in dichloromethane (15 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 955 mg, 4.98 mmol, 1.25 equivalents) was added, and the reaction mixture was stirred at room temperature overnight. The solution was diluted with dichloromethane (50 ml), which was further washed with saturated sodium bicarbonate (25 ml), water (25 ml), salt (25 ml) and dried over Mg2SO4. The solvent was removed in vacuo to give tert-butyl A- (ethyl(m-tolyl)carbamoyl)benzylcarbamate. Without purification, the acylation product was treated with 50% TFA in dichloromethane (25 ml) at room temperature for 20 minutes. The reaction mixture was condensed to give the yellow oil which was further purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10-40% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product as the TFA salt (1.172g, 77% in 2 steps). MS: calcd for C17H20N2O+H+ 269.36, found 269.20.
Preparation of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline
Figure imgf000084_0001
A mixture of cyanuric chloride (520 mg, 2.82 mmol, lequivalent) in CH3CN/H2O (1/1, 20 ml) was cooled to 00C. 6,7-Dimethoxy-l,2,3,4- tetrahydroisoquinoline hydrochloride (647.2 mg, 2.82 mmol, 1 equivalent) was added. The reaction mixture was adjusted to a pH of about 9-10 using IN NaOH. The reaction was stirred at cold for about 20 min, during which a white solid was formed. The solid was collected by filtration to give the desired product with >95% purity (755.5 mg, 79% yield). MS: calcd for C14H14C12N4O2+H+ 341.06, found 341.19.
Preparation of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-l,2,3,4-tetrahydroisoquinoline
Figure imgf000084_0002
A mixture of cyanuric chloride (544 mg, 2.95 mmol, 1 equivalent) in CH3CN/H2O (1/1, 20 ml) was cooled to 00C. 1,2,3,4-Tetrahydroisoquinoline hydrochloride (500.5 mg, 2.95 mmol, 1 equivalent) was added. The reaction mixture was adjusted to a pH of about 9-10 using IN NaOH. The reaction was stirred at cold for 20 min, during which a white solid was formed. The solid was collected by filtration to give the desired product with >95% purity (774.5 mg, 93.5% yield). MS: calcd for C12H10C12N4+H+ 281.04, found 281.19.
Preparation of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)- l,3,5-triazin-2-ylamino)methyl)-Λ7-ethyl-Λf-rø-tolylbenzamide
Figure imgf000085_0001
To a mixture of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline (0.15 mmol, 1 equivalent) in CΗ3CN/Η2O (1/1, ~ 4 ml) was added 4-(aminomethyl)-N-ethyl-N-m-tolylbenzamide as the TFA salt (58 mg, 0.15 mmol, 1 equivalent). The pH of the reaction mixture was adjusted with IN NaOH to about 9-10, and the reaction was stirred at room temperature overnight. LC-MS showed the complete conversion to the desired product. Without workup, the product in the reaction solution will be used directly for the next step. The pure product can be obtained through the purification with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 40-95% CH3CΝ/H2O, 0.1% TFA, 20 min). MS: calcd for C31H33C1N6O3+H+ 573.24, found 573.3.
Preparation of 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-.<V-rø-tolylbenzamide
Figure imgf000085_0002
To a mixture of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-l,2,3,4-tetrahydroisoquinoline (30 mg, 0.107 mmol, 1 equivalent) in CH3CN/H2O (1/1, 2 ml) was added A- (aminomethyl)-N-ethyl-N-m-tolylbenzamide as the TFA salt (41 mg, 0.107 mmol, 1 equivalent). The pH of the reaction mixture was adjusted with IN NaOH to about 9-10, and the reaction was stirred at room temperature overnight. LC-MS showed complete conversion to the desired product. Without workup, the product in the reaction solution will be used directly for the next step. The pure product can be obtained through the purification with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 40-95% CH3CΝ/H2O, 0.1% TFA, 20 min). MS: calcd for C29H29C1N6O+H+ 513.22, found 513.30.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6- (methylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø-tolylbenzamide
Figure imgf000086_0001
The above solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, - 0.8 ml) was treated with methylamine (40% in water, 16 μl, 0.20 mmol, 7 equivalents) at 800C for 2 hours. The reaction mixture was condensed down to give the crude product which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10-60% CH3CN/H2O, 0.1% TFA, 16 min). MS: calcd for C32H37N7O3+H+ 568.70, found 568.40.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000087_0001
The solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.293 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 10 ml) was treated with 2-(4-methyl-piperazin-l-yl)-ethylamine (168 μl, 1.172 mmol, 4 equivalents) at 800C for 7 hours. The reaction mixture was condensed down to give the crude product which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10-60% CH3CN/H2O, 0.1% TFA, 16 min) to give the desired product as a TFA salt (76.4 mg, 33% yield in 2 steps). MS: calcd for C38H49N9O3+H+ 680.88, found 680.5.
Example of a preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000087_0002
To the solution of 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (8 mg, 0.0156 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 1 ml) was added 2-(4-methyl-piperazin-l-yl> ethylamine (20 mg, 0.142 mmol, 9 equivalents). The reaction was heated at 8O0C overnight. The reaction solution was condensed down to give the residue which was acidified and purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-80% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product as a TFA salt. MS: calcd for C36H45N9O+H+ 620.38, found 620.44.
Example of a preparation of 4-((4-(benzylamino)-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000088_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, - 0.8 ml) was added benzylamine (22 μl, 0.2 mmol, 6.7 equivalents). The reaction mixture was heated at 800C for 2 hours. The solution was condensed down to give the crude product which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-75% CH3CN/H2O, 0.1% TFA, 16 min). MS: calcd for C38H41N7O3+H+ 644.80, found 644.5.
Example of a preparation of 4-((4-(benzylamino)-6-(3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000088_0002
To the reaction solution for the preparation of 4-((4-chloro-6-(3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in ΝMP (1 ml) was added benzylamine (16.5 μl, 0.15 mmol, 5 equivalents). The reaction mixture was heated at 800C for 3-4 hours. The solvent was evaporated in vacuo and the residue was further purified with PR-HPLC to give the desired product (4.54 mg). MS: calcd for C36H37N7O+H+ 584.75, found 584.5.
Example of a preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-
6-(2-(furan-2-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000089_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, - 0.8 ml) was added 2- furan-2-yl-ethylamine (22 mg, 0.2 mmol, 6.7 equivalents). The reaction mixture was stirred at 800C for 2 hours. The solvent was evaporated and the residue was acidified and purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-80% CH3CN/H2O, 0.1% TFA, 16 min) to give the desired product. MS: calcd for C37H41N7O4+H+ 648.79, found 648.4.
Example of a preparation of 4-((4-(cyclohexylamino)-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000089_0002
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, - 0.8 ml) was added cyclohexylamine (24 μl, 0.21 mmol, 7 equivalents). The reaction was heated at 800C for 2 hours. The solvent was evaporated in vacuo to give the residue which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-80% CH3CN/H2O, 0.1% TFA, 16 min). MS: calcd for C37H45N7O3+H+ 636.82, found 636.5.
Example of a preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-
6-(2-(thiophen-2-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000090_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in ΝMP (1 ml) was added 2- thiopheneethylamine (19.5 mg, 0.15 mmol, 5 equivalents). The reaction mixture was heated at 800C for 3-4 hours. The solvent was evaporated in vacuo to give the residue which was further purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 36-78% CΗ3CΝ/Η2O, 0.1% TFA, 18 min). MS: calcd for C37H41N7O3S+H+ 664.85, found 664.4.
Example of a preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)- 6-(isopropylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø-tolylbenzamide
Figure imgf000091_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in ΝMP (1 ml) was added isopropylamine (9 mg, 0.15 mmol, 5 equivalents). The reaction mixture was heated at 800C for 3-4 hours. The solvent was evaporated in vacuo to give the residue which was further purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 36-75% CΗ3CΝ/Η2O, 0.1% TFA, 18 min). MS: calcd for C34H41N7O3+H+ 596.76, found 596.5.
Example of a preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)- 6-(phenylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø-tolylbenzamide
Figure imgf000091_0002
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.03 mmol, 1 equivalent) in ΝMP (1 ml) was added aniline (14 mg, 0.15 mmol, 5 equivalents). The reaction mixture was heated at 800C for 3-4 hours. The solvent was evaporated in vacuo to give the residue which was further purified with RP- ΗPLC (Luna, 5μ C8(2), 100x21mm, 36-70% CΗ3CΝ/Η2O, 0.1% TFA, 18 min). MS: calcd for C37H39N7O3+H+ 630.77, found 630.5. Example of a preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-
6-(2-(dimethylamino)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000092_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.058 mmol, 1 equivalent) in ΝMP (~1 ml) was added N,N- dimethylethylenediamine (52.8 mg, 0.6 mmol, -10 equivalents). The reaction mixture was heated at 800C for 5 hours. The solution was neutralized with IN HCl. The solvent was evaporated in vacuo and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 20-95% CΗ3CΝ/Η2O, 0.1% TFA, 20 min) to give the desired product as a TFA salt (2.1 mg). MS: calcd for C35H44N8O3+H+ 625.80, found 625.42.
Example of a preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-
(dimethylamino)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000092_0002
The solution of 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin- 2-ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (8 mg, 0.0156 mmol, 1 eq) in CΗ3CΝ/Η2O (1/1, 2 ml) was treated with N,N-dimethylethylenediamine in CH3CN (0.2 M, 650 μl, 0.13 mmol, 8.3 equivalents) at 8O0C overnight. The solvent was evaporated and the crude was purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 25-85% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product as a TFA salt (10 mg, -100%). MS: calcd for C33H40N8O+H+ 565.33, found 565.39.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-hydroxy- l,3,5-triazin-2-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000093_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.04 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, -3 ml) was added 6N HCl (0.3 ml). The reaction mixture was heated at 8O0C overnight. The solvent was evaporated in vacuo and the crude was purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CH3CN/H2O, 0.1% TFA, 17 min) to give the desired product (10.1 mg, 45% yield). MS: calcd for C31H34N6O4+H+ 555.64, found 555.33.
Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-hydroxy-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-.<V-rø-tolylbenzamide
Figure imgf000093_0002
To the reaction solution of the preparation of 4-((4-chloro-6-(3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-20 mg, 0.04 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 0.7 ml) was added 6N HCl (0.3 ml). The reaction mixture was heated at 8O0C overnight. The solvent was evaporated in vacuo and the crude was purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-75% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired compound (13.73 mg, -70% yield). MS: calcd for C29H30N6O2+H+ 495.61, found 495.30.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin- 2-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000094_0001
To the solution of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (~2 mg) in MeOH (1 ml) was added 10% Pd/C (2 mg). The reaction mixture was stirred under an H2 balloon at room temperature for 2 hours. The reaction solution was filtered through celite and concentrated. The crude product was purified with RP-HPLC to give the desired compound (0.25 mg). MS: calcd for C31H34Ν6O3+H+ 539.66, found 539.39.
Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-.<V-rø-tolylbenzamide
Figure imgf000094_0002
To the solution of 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (7 mg) in MeOH (0.8 ml) was added 10% Pd/C (2 mg). The reaction mixture was stirred under an H2 balloon at room temperature for 1 hour. The reaction solution was filtered through celite and concentrated. The crude product was purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-85% CH3CΝ/H2O, 0.1% TFA, 17 min) to give the desired compound (4 mg, 61.5%). MS: calcd for C29H30N6O+H+ 479.59, found 479.35. Preparation of 2-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(4-(ethyl(rø- tolyl)carbamoyl)benzylamino)-l,3,5-triazin-2-ylamino)acetic acid
Figure imgf000095_0001
To the reaction solution for the preparation of 4-((4-chloro-6-(6,7-dimethoxy- 3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-m- tolylbenzamide (-0.044 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 5 ml) was added H- Glycine-OMe hydrochloride (55.25 mg, 0.44 mmol, 10 equivalents). The pH of the reaction solution was adjusted to around 9-10 by adding IN NaOH. The reaction was heated at 800C overnight. Neutralize the solution with HCl. The solvent was evaporated in vacuo and the crude was purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20- 85% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product (14.25 mg, 58% yield). MS: calcd for C33H37N7O5+H+ 612.29, found 612.3.
Scheme 2
Figure imgf000096_0001
Preparation of 4-(aminomethyl)-Λ^-ethyl-Λ^-methylbenzamide
Figure imgf000096_0002
To a solution of 4-(Boc-aminomethyl)benzoic acid (0.534 g, 2.125 mmol, 1 equivalent) in DMF (8 ml) was added HATU (807 mg, 2.125 mmol, 1 equivalent) in DMF (5 ml), followed by adding DIEA (740 μl, 4.25 mmol, 2 equivalents). After being stirred at room temperature for 5 min, N-ethylmethylamine (219 μl, 2.55 mmol, 1.25 equivalents) was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was evaporated and the residue was redis solved in EtOAc, which was further washed with sat. ΝaHCU3, water, salt and dried over MgSO4. The solvent was removed in vacuo to give the crude which was purified with silicon chromatography (eluant: 60-70% EtOAc/Hexane). The product was collected and condensed to give the residue which was redissolved in dichloromethane (20 ml). TFA (20 ml) was added and the solution was stirred at room temperature for 1 hour. The solvents were evaporated to give the desired product which was lypholized to get rid of the extra TFA and would be used without further purification. MS: calcd for C11H16N2O+H+ 193.14, found 193.03.
Preparation of 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-Λ7-methylbenzamide
Figure imgf000097_0001
To a solution of 2-(4,6-dichloro- 1,3, 5-triazin-2-yl)- 1,2,3,4- tetrahydroisoquinoline (54.7 mg, 0.195 mmol, 1 equivalent) in dichloromethane (2 ml) was added 4-(aminomethyl)-N-ethyl-N-methylbenzamide as the TFA salt (-80 mg, 0.261 mmol, 1.34 equivalents), followed by adding triethylamine (144 μl, 1 mmol, 5 equivalents). The reaction was stirred at room temperature for about 1 hour. The solvent was evaporated and the residue was washed with water to give the white solid which will be used directly for the next step. MS: calcd for C23Η25C1Ν6O+Η+ 437.19, found 437.3.
Preparation of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)- l,3,5-triazin-2-ylamino)methyl)-A?-ethyl-iV-methylbenzamide
Figure imgf000097_0002
To a solution of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline (46.59 mg, 0.1366 mmol, 1 equivalent) in dichloromethane (2 ml) was added 4-(aminomethyl)-N-ethyl-N-methylbenzamide as the TFA salt (-70 mg, 0.23 mmol, 1.34 equivalents), followed by adding triethylamine (144 μl, 1 mmol, 5 equivalents). The reaction was stirred at room temperature for about 1 hour. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 30-75% CΗ3CΝ/Η2O, 0.1% TFA, 20 min) to give the desired product (30 mg, 44% yield). MS: calcd for C25H29C1N6O3+H+ 497.21, found 497.3. Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-Λ7-methylbenzamide
Figure imgf000098_0001
To a solution of crude 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (-25 mg, -0.05 mmol, 1 equivalent) in MeOH (1 ml) and dichloromethane (0.5 ml) was added 10% Pd/C (-70 mg). Under an Η2 balloon, the reaction mixture was stirred at room temperature for 2.5 hours. The solid was filtered and the solution was condensed to give the crude which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-60% CH3CΝ/H2O, 0.1% TFA, 20 min) to give the desired product (3.1 mg). MS: calcd for C23H26N6O+H+ 403.23, found 403.4.
Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-
(dimethylamino)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^- methylbenzamide
Figure imgf000098_0002
To a solution of crude 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (-25 mg, -0.05 mmol, 1 equivalent) in ΝMP (1 ml) was added N,N-dimethylethylenediamine (200 μl, 1.8 mmol, 36 equivalents). The reaction mixture was heated at 8O0C overnight. After being neutralized with IN HCl, the reaction solution was directly put on RP-ΗPLC for purification to give the desired product as a TFA salt (6.7 mg, -22% yield in 2 steps). MS: calcd for C27Η36Ν8O+Η+ 489.31, found 489.34. Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-(ethyl(methyl)amino)- l,3,5-triazin-2-ylamino)methyl)-Λ7-ethyl-Λ7-methylbenzamide
Figure imgf000099_0001
To a solution of crude 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (-25 mg, -0.05 mmol, 1 equivalent) in ΝMP (1 ml) was added N-methylethanamine (200 μl, 2.3 mmol, 46 equivalents). The reaction mixture was heated at 800C for 2 hours. The solvent was evaporated in vacuo and the crude was purified with RP-ΗPLC to give the desired product (8.2 mg, -37% yield in 2 steps). MS: calcd for C26Η33Ν7O+Η+ 460.28, found 460.37.
Preparation of 4-((4-(3,4-dihydroisoquinolin-2(lH)-yl)-6-(4-methylpiperazin-l-yl)- l,3,5-triazin-2-ylamino)methyl)-A?-ethyl-iV-methylbenzamide
Figure imgf000099_0002
To a solution of crude 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (-0.065 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 1 ml) was added 1-methylpiperazine (65 mg, 0.65 mmol, 10 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction solution was neutralized and directly purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10- 50% CH3CN/H2O, 0.1% TFA, 19 min) to give the desired product as a TFA salt (20 mg, -40% yield in 2 steps). MS: calcd for C28H36N8O+H+ 501.31, found 501.27. Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(4- methylpiperazin-l-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-methylbenzamide
Figure imgf000100_0001
To a solution of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (6 mg, 0.012 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 1 ml) was added 1-methylpiperazine (12 mg, 0.12 mmol, 10 equivalents). The reaction mixture was heated at 800C overnight. The reaction solution was neutralized and directly purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 4-40% CH3CN/H2O, 0.1% TFA, 19 min) to give the desired product as a TFA salt (2.5 mg, 31% yield). MS: calcd for C30H40N8O3+H+ 561.33, found 561.27.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-
(dimethylamino)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^- methylbenzamide
Figure imgf000100_0002
To a solution of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (6 mg, 0.012 mmol, 1 equivalent) in CΗsCΝ/t^O (1/1, 1 ml) was added N,N-dimethylethylenediamine (10.6 mg, 0.12 mmol, 10 equivalents). The reaction mixture was heated at 800C overnight. The reaction solution was neutralized and directly purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 4-40% CΗ3CΝ/Η2O, 0.1% TFA, 19 min) to give the desired product as a TFA salt (2 mg, 25% yield). MS: calcd for C29H40N8O3+H+ 549.33, found 549.23.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^- methylbenzamide
Figure imgf000101_0001
To a solution of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (6 mg, 0.012 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 1 ml) was added 2-(4-methyl-piperazin-l-yl> ethylamine (17 mg, 0.12 mmol, 10 equivalents). The reaction mixture was heated at 800C overnight. The reaction solution was neutralized and directly purified with RP- HPLC (Luna, 5μ C8(2), 100x21mm, 4-40% CH3CN/H2O, 0.1% TFA, 19 min) to give the desired product as a TFA salt (3.5 mg, 35% yied). MS: calcd for C32H45N9O3+H+ 604.37, found 604.28.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin- 2-ylamino)methyl)-Λ7-ethyl-.<V-methylbenzamide
Figure imgf000101_0002
To a solution of 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide (12 mg, 0.024 mmol, 1 equivalent) in MeOH (1 ml) was added 10% Pd/C (~8 mg). Under an H2 balloon, the reaction mixture was stirred at room temperature for 40 min. The solid was filtered and the solution was condensed to give the crude which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 30-60% CH3CΝ/H2O, 0.1% TFA, 20 min) to give the desired product (1.3 mg, 11.6% yield). MS: calcd for C25H30N6O3+H+ 463.25, found 463.4.
Scheme 3
Figure imgf000102_0001
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)benzoic acid
Figure imgf000102_0002
To the mixture of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline (100 mg, 0.293 mmol, 1 equivalent) in CH3CN/H2O (1/1, 8 ml) was added 4-(aminomethyl)benzoic acid methyl ester (59.1mg, 0.293 mmol, 1 equivalent). The pH of the reaction solution was kept at about 9-10 by adding IN NaOH. The reaction was stirred at room temperature overnight. The solvent was removed in vacuo to give the crude product which would be used directly for the next step.
Methyl 4-((4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)benzoate (0.15 mmol, 1 equivalent) was dissolved in NMP (3 ml). 2-(4-methyl-piperazin-l-yl)-ethylamine (125.88 mg, 0.88 mmol, 6 equivalents) was added, and the reaction mixture was heated at 800C for 5 hours. LC-MS showed the reaction has completed. 2/3 (0.1 mmol) of the reaction mixture was further treated with IN NaOH (0.4 ml, 0.4 mmol, 4 equivalents). The reaction mixture was stirred at room temperature overnight. The reaction solution was neutralized and condensed to give the crude which was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 15-95% CΗ3CN/Η2O, 0.1% TFA, 20 min) to give the desired product as a TFA salt (26.2 mg, -33% in 3 steps). MS: calcd for C29H38N8O4+H+ 563.68, found 563.4.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-rø- tolylbenzamide
Figure imgf000103_0001
A solution of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)benzoic acid (8 mg, 0.01 mmol, 1 equivalent), m-toluidine (1.76 μl, 0.0162 mmol, 1.6 equivalents)) and DMAP (0.3 mg, 0.003 mmol, 0.3 equivalents) in dichloromethane (1 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 3.41 mg, 0.0178 mmol, 1.8 equivalents) was added, and the reaction mixture was stirred at 00C for 2 hours and at room temperature overnight. The solution was diluted with dichloromethane, which was further washed with saturated sodium bicarbonate, water, salt and dried over MgSO4. The solvent was removed in vacuo to give the crude compound, which was further purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10-95% CH3CN/H2O, 0.1% TFA, 15 min) to give the desired product as a TFA salt. MS: calcd for C36H45N9O3+H+ 652.82, found 652.42.
Preparation of 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-6-(2-(4- methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^- methylbenzamide
Figure imgf000104_0001
Following the same procedure as preparation of 4-((4-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-6-(2-(4-methylpiperazin- l-yl)ethylamino)- 1 ,3,5-triazin-2- ylamino)methyl)-N-m-tolylbenzamide, 4-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin- 2(lH)-yl)-6-(2-(4-methylpiperazin-l-yl)ethylamino)-l,3,5-triazin-2- ylamino)methyl)benzoic acid (8 mg, 0.01 mmol, 1 equivalent) in dichloromethane (1 ml) was coupled with methylamine (2.M in TΗF, 8 μl, 0.016 mmol, 1.6 equivalents) under the activation of EDCI (3.41 mg, 0.0178 mmol, 1.8 equivalents) and DMAP (0.3 mg, 0.003 mmol, 0.3 equivalent). The crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 10-95% CΗ3CΝ/Η2O, 0.1% TFA, 15 min) to give the desired product as a TFA salt (1.23 mg, 15% yield). MS: calcd for C30H42N9O3+H+ 576.71, found 576.38. Scheme 4
Figure imgf000105_0001
Preparation of 4-chloro-Λ^-cyclohexyl-6-(6,7-dimethoxy-3,4-dihydroisoquinolin- 2(lH)-yl)-l,3,5-triazin-2-amine
Figure imgf000105_0002
To the solution of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline (157 mg, 0.46 mmol, 1 equivalent) in CH3CN/H2O (1/1, 10 ml)was added cyclohexylamine (52.7 μl, 0.46 mmol, 1 equivalent). The pH of the reaction mixture was adjusted with IN NaOH to about 9-10, and the reaction was stirred at room temperature for 1 hour. Without workup, the reaction solution will be used directly for the next step. Preparation of N-benzyl-4-chloro-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)-l,3,5-triazin-2-amine
Figure imgf000106_0001
To the solution of 2-(4,6-dichloro-l,3,5-triazin-2-yl)-6,7-dimethoxy-l,2,3,4- tetrahydroisoquinoline (43 mg, 0.126 mmol, 1 equivalent) in CΗ3CN/Η2O (1/1, 2 ml) was added benzylamine (13.7 μl, 0.126 mmol, 1 equivalent). The pH of the reaction mixture was adjusted to about 9-10 with IN NaOH (126 μl, 1 equivalent), and the reaction was stirred at room temperature for 1 hour. Without workup, the reaction solution will be used directly for the next step.
Preparation of Λ^-benzyl-Λ^-cyclohexyl-β-CβjT-dimethoxy-S^-dihydroisoquinolin- 2(lH)-yl)-l,3,5-triazine-2,4-diamine
Figure imgf000106_0002
To the above reaction solution of N-benzyl-4-chloro-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-amine (-0.126 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 2 ml) was added cyclohexylamine (29 μl, 0.252 mmol, 2 equivalents), followed by adding IN NaOH (126 μl, 0.126 mmol, 1 equivalent). The reaction mixture was heated at 8O0C overnight. The solvent was evaporated and the residue was acidified and purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 25-75% CH3CN/H2O, 0.1% TFA, 17 min) to give the desired product. MS: cacld for C27H34N6O2+H+ 475.28, found 475.4. Preparation of Λ^2-benzyl-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-Λ^-(2- (4-methylpiperazin-l-yl)ethyl)-l,3,5-triazine-2,4-diamine
Figure imgf000107_0001
To the above reaction solution of N-benzyl-4-chloro-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-amine (0.126 mmol, 1 equivalent) in CΗ3CΝ/Η2O (1/1, 2 ml) was added 2-(4-methyl-piperazin-l-yl)-ethylamine (36 mg, 0.252 mmol, 2 equivalents), followed by adding IN NaOH (126 μl, 0.126 mmol, 1 equivalent). The reaction mixture was heated at 8O0C overnight. The solvent was evaporated and the residue was acidified and purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 10-60% CH3CN/H2O, 0.1% TFA, 17 min) to give the desired product. MS: cacld for C28H38N8O2+H+ 519.32, found 519.4.
Preparation of 4-((4-(cyclohexylamino)-6-(6,7-dimethoxy-3,4-dihydroisoquinolin- 2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)benzoic acid
Figure imgf000107_0002
To the above reaction solution of 4-chloro-N-cyclohexyl-6-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(lH)-yl)-l,3,5-triazin-2-amine (0.46 mmol, 1 equivalent) was added methyl 4-(aminomethyl)benzoate hydrochloride (371 mg, 1.84 mmol, 4 equivalents), followed by adding IN ΝaOΗ (~ 2.76 ml, 2.76 mmol, 6 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction mixture was cooled down and further treated with ~2M KOΗ (2 ml) at room temperature for 2 hours. The solvent was evaporated and the residue was acidified and purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 20-95% CΗ3CΝ/Η2O, 0.1% TFA, 20 min) to give the desired product. MS: cacld for C28H34N6O4+H+ 519.63, found 519.37. Preparation of 4-((4-(cyclohexylamino)-6-(6,7-dimethoxy-3,4-dihydroisoquinolin- 2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ7-methylbenzamide
Figure imgf000108_0001
A solution of 4-((4-(cyclohexylamino)-6-(6,7-dimethoxy-3,4-dihydroisoquinolin- 2(lH)-yl)-l,3,5-triazin-2-ylamino)methyl)benzoic acid (13.3 mg, 0.0257 mmol, 1 equiuvalent), methylamine (2.0M in TΗF, 66 μl, 5 equivalents) and DMAP (0.6 mg, 0.005 mmol, 0.2 equivalents) ) in dichloromethane (2 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 6.15 mg, 0.0321 mmol, 1.25 equivalents) was added, and the reaction mixture was stirred at room temperature overnight. The solution was diluted with dichloromethane, which was further washed with saturated sodium bicarbonate, water, salt and dried over MgSO4. The solvent was removed in vacuo to give the crude compound, which was further purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 20-95 CΗ3CN/Η2O, 0.1% TFA, 20 min) to give the desired product (1.42 mg, 10% yield ). MS: calcd for C29H37N7O3+H+ 532.67, found 532.37.
Scheme 5
Figure imgf000108_0002
Preparation of 4-((6-chloropyrimidin-4-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000109_0001
A solution of 4,6-dichloropyrimidine (50.7 mg, 0.34 mmol, 1 equivalent) in DMF (1.5 ml) was added 4-(aminomethyl)-N-ethyl-N-m-tolylbenzamide as a TFA salt (130 mg, 0.34 mmol, 1 equivalent), followed by adding triethylamine (94.8 μl, 0.68 mmol, 2 equivalents). The reaction was heated at 800C for 2 hours. LC-MS showed the completion of the reaction. The reaction solution will be used directly for the next step. MS: calcd for C21H21C1Ν4O+H+ 381.15, found 381.2.
Preparation of 4-((6-(3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- ylamino)methyl)-Λ7-ethyl-.<V-rø-tolylbenzamide
Figure imgf000109_0002
1/3 of the above reaction solution to prepare 4-((6-chloropyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (~0.l l mmol, 1 equivalent) was added the solution of 1,2,3,4-tetrahydroisoquinoline hydrochloride (74.6 mg, 0.44 mmol, 4 equivalents) in DMF (0.5 ml), followed by adding triethylamine (76.7 μl, 0.55 mmol, 5 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25- 70% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (18.9 mg, -40% in 2 steps). MS: calcd for C30H31N5O+H+ 478.26, found 478.32. Preparation of 4-((6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000110_0001
1/3 of the above reaction solution to prepare 4-((6-chloropyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (~0.l l mmol, 1 equivalent) was added the solution of 6,7-dimethoxy-l,2,3,4-tetrahydroisoquinoline hydrochloride (101.1 mg, 0.44 mmol, 4 equivalents) in DMF (0.5 ml), followed by adding triethylamine (76.7 μl, 0.55 mmol, 5 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25-65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (22.6 mg, -42% in 2 steps). MS: calcd for C32H35N5O3+H+ 538.28, found 538.32.
Preparation of 4-((6-chloro-2-methylpyrimidin-4-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000110_0002
A solution of 4,6-dichloro-2-methylpyrimidine (50.7 mg, 0.311 mmol, 1 equivalent) in DMF (1.5 ml) was added 4-(aminomethyl)-N-ethyl-N-m-tolylbenzamide as a TFA salt (118.8 mg, 0.311 mmol, 1 equivalent), followed by adding triethylamine (86.7 μl, 0.68 mmol, 2 equivalents). The reaction was heated at 8O0C for 2 hours. LC- MS showed the completion of the reaction. The reaction solution will be used directly for the next step. MS: calcd for C22H23C1Ν4O+H+ 395.16, found 395.2. Preparation of 4-((6-(3,4-dihydroisoquinolin-2(lH)-yl)-2-methylpyrimidin-4- ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000111_0001
1/3 of the above reaction solution to prepare 4-((6-chloro-2-methylpyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.104 mmol, 1 equivalent) was added the solution of 1,2,3,4-tetrahydroisoquinoline hydrochloride (70.6 mg, 0.41 mmol, 4 equivalents) in DMF (1 ml), followed by adding triethylamine (72.5 μl, 0.52 mmol, 5 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25- 65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (17.2 mg, -35% in 2 steps). MS: calcd for C31H33N5O+H+ 492.28, found 492.32.
Preparation of 4-((6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-2- methylpyrimidin-4-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000111_0002
1/3 of the above reaction solution to prepare 4-((6-chloro-2-methylpyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.104 mmol, 1 equivalent) was added the solution of 6,7-dimethoxy-l,2,3,4-tetrahydroisoquinoline hydrochloride (95.6 mg, 0.416 mmol, 4 equivalents) in DMF (0.5 ml), followed by adding triethylamine (72.5 μl, 0.52 mmol, 5 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25-65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (21 mg, -38% in 2 steps). MS: calcd for C33H37N5O3+H+ 552.30, found 552.35. Preparation of 4-((2-amino-6-chloropyrimidin-4-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000112_0001
A solution of 4,6-dichloropyrimidin-2-amine (50.0 mg, 0.305 mmol, 1 equivalent) in DMF (1.5 ml) was added 4-(aminomethyl)-N-ethyl-N-m-tolylbenzamide as a TFA salt (116.46 mg, 0.305 mmol, 1 equivalent), followed by adding triethylamine (85 μl, 0.61 mmol, 2 equivalents). The reaction was heated at 800C for 2 hours. LC-MS showed the completion of the reaction. The reaction solution will be used directly for the next step. MS: calcd for C21H22C1Ν5O+H+ 396.16, found 396.2.
Preparation of 4-((2-amino-6-(3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- ylamino)methyl)-Λ7-ethyl-.<V-rø-tolylbenzamide
Figure imgf000112_0002
1/2 of the above reaction solution to prepare 4-((2-amino-6-chloropyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.15 mmol, 1 equivalent) was added the solution of 1,2,3,4-tetrahydroisoquinoline hydrochloride (101.8 mg, 0.6 mmol, 4 equivalents) in DMF (0.5 ml), followed by adding triethylamine (111.5 μl, 0.8 mmol, 6 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25- 65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (8.7 mg, -12% in 2 steps). MS: calcd for C30H32N6O+H+ 493.27, found 493.33.
-Il l- Preparation of 4-((2-amino-6-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)- yl)pyrimidin-4-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000113_0001
1/2 of the above reaction solution to prepare 4-((2-amino-6-chloropyrimidin-4- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.15 mmol, 1 equivalent) was added the solution of 6,7-dimethoxy-l,2,3,4-tetrahydroisoquinoline hydrochloride (137.8 mg, 0.6 mmol, 4 equivalents) in DMF (0.5 ml), followed by adding triethylamine (111.5 μl, 0.8 mmol, 6 equivalents). The reaction was heated at 115°C over weekend. The solvent was evaporated and the crude was purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 25-65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (13.5 mg, -16% in 2 steps). MS: calcd for C32H36N6O3+H+ 553.29, found 553.33.
Scheme 6
Figure imgf000113_0002
Preparation of 4-((4-chloro-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø- tolylbenzamide
Figure imgf000114_0001
At 00C, the solution of 2,4-dichloro-l,3,5-triazine (95%, 20.4 mg, 0.13 mmol, 1 equivalent) and 4-(aminomethyl)-N-ethyl-N-m-tolylbenzamide as a TFA salt (52 mg, 0.136 mmol, 1 equivalent) in ΝMP (1.5 ml) was added diisopropylethylamine (59 μl, 0.34 mmol, 2.5 equivalents). The reaction was stirred at cold for 1-2 hours, followed by stirring at room temperature overnight. The reaction solution will be used directly for the next step. MS: calcd for C20H20ClΝ5O+H+ 382.14, found 382.2.
Preparation of N-ethyl-4-((4-(7-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-Λ^-rø-tolylbenzamide
Figure imgf000114_0002
1/5 of the above reaction solution to prepare 4-((4-chloro-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.025 mmol, 1 equivalent) was added the solution of 7-fluoro-l,2,3,4-tetrahydroisoquinoline (21 mg, 0.136 mmol, 5 equivalents) in ΝMP (0.5 ml). The reaction was heated at 800C for 1 hour. The reaction solution was neutralized and directly purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (5.5 mg, -46% in 2 steps). MS: calcd for C29H29FN6O+H+ 496.25, found 497.34. Preparation of Λ^-ethyl-4-((4-(6-fluoro-3,4-dihydroisoquinolin-2(lH)-yl)-l,3,5- triazin-2-ylamino)methyl)-Λ^-rø-tolylbenzamide
Figure imgf000115_0001
1/5 of the above reaction solution to prepare 4-((4-chloro-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.025 mmol, 1 equivalent) was added the solution of 6-fluoro-l,2,3,4-tetrahydroisoquinoline (21 mg, 0.136 mmol, 5 equivalents) in ΝMP (0.5 ml). The reaction was heated at 800C for 1 hour. The reaction solution was neutralized and directly purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CΗ3CΝ/Η2O, 0.1% TFA, 17 min) to give the desired product (4.7 mg, -39% in 2 steps). MS: calcd for C29H29FN6O+H+ 496.25, found 497.36.
Preparation of Λ^-ethyl-4-((4-(isoindolin-2-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ^-rø- tolylbenzamide
Figure imgf000115_0002
1/5 of the above reaction solution to prepare 4-((4-chloro-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.025 mmol, 1 equivalent) was added the solution of isoindoline (15.4 μl, 0.136 mmol, 5 equivalents) in ΝMP (0.5 ml). The reaction was heated at 800C for 1 hour. The reaction solution was neutralized and directly purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CH3CΝ/H2O, 0.1% TFA, 17 min) to give the desired product (5.3 mg, -46% in 2 steps). MS: calcd for C28H28N6O+H+ 465.24, found 465.34. Preparation of 4-((4-(3,4-dimethoxybenzylamino)-l,3,5-triazin-2-ylamino)methyl)- Λ^-ethyl-Λ^-rø -tolylbenzamide
Figure imgf000116_0001
1/5 of the above reaction solution to prepare 4-((4-chloro-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.025 mmol, 1 equivalent) was added the solution of (3,4-dimethoxyphenyl)methanamine (22.7 mg, 0.136 mmol, 5 equivalents) in ΝMP (0.5 ml). The reaction was heated at 800C for 1 hour. The reaction solution was neutralized and directly purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CH3CΝ/H2O, 0.1% TFA, 17 min) to give the desired product (5.3 mg, -46% in 2 steps). MS: calcd for C29H32N6O3+H+ 513.26, found 513.22.
Preparation of Λ^-ethyl-4-((4-(piperidin-l-yl)-l,3,5-triazin-2-ylamino)methyl)-Λ^-rø- tolylbenzamide
Figure imgf000116_0002
1/5 of the above reaction solution to prepare 4-((4-chloro-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (-0.025 mmol, 1 equivalent) was added the solution of piperidine (13.5 μl, 0.136 mmol, 5 equivalents) in ΝMP (0.5 ml). The reaction was heated at 800C for 1 hour. The reaction solution was neutralized and directly purified with RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CH3CΝ/H2O, 0.1% TFA, 17 min) to give the desired product (6.7 mg, -62% in 2 steps). MS: calcd for C25H30N6O+H+ 431.26, found 431.33. Scheme 7
Figure imgf000117_0001
Preparation of (lr,4r)-4-(aminomethyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000117_0002
A solution of trans 4-(Boc-aminomethyl)cyclohexanecarboxylic acid (0.25 g, 0.971 mmol, 1 equivalent) in DMF (12 ml) was added HATU (369.2 mg, 0.971 mmol, 1 equivalent), followed by adding DIEA (338 ul, 1.94 mmol, 2 equivalents). 4-Amino-N- (5-methyl-l,3,4-thiadiazol-2-yl)benzenesulfonamide (262.5 mg, 0.971 mmol, 1 equivalent) was added to the reaction mixture. The reaction was stirred at room temperature for 1 hour. The solution was concentrated and the crude product was further purified with silica chromatography (Eluant: 85% EtOAc in Hexane) to give the desired acylation product fe?t-butyl ((lr,4r)-4-(4-(N-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenylcarbamoyl)cyclohexyl)methylcarbamate. MS: calcd for C22H37Ν5O5S2+Νa+ 532.18, found 532.08.
The acylation product was treated with 20% TFA in dichloromethane at room temperature for 1 hour. The reaction mixture was condensed to give the desired product which will be used without further purification. MS: calcd for C17H23N5O3S2+H+ 410.12, found 410.10.
Preparation of 4,6-dichloro-Λ7-(2,3-dimethylbenzyl)- l,3,5-triazin-2-amine
Figure imgf000118_0001
A mixture of cyanuric chloride (20 mg, 0.11 mmol, lequivalent) in CH3CN/H2O (1/1, 2 ml) was cooled to 00C. 2,3-Dimethylbenzylamine (14.78 mg, 0.11 mmol, 1 equivalent) was added. The reaction mixture was adjusted to a pH of about 9-10 using IN NaOH. Total about 1 equivalent of base was required. The reaction was completed in about 1 hour. Without work-up and purification, it was used for the next amine addition in the same reaction vessel. MS: calcd for C12H12C12N4+H+ 283.04, found 282.99. Preparation of 4,6-dichloro-Λ^-(3-chloro-2-methylbenzyl)-l,3,5-triazin-2-amine
Figure imgf000118_0002
A mixture of cyanuric chloride (10 mg, 0.055 mmol, 1 equivalent) in CH3CN/H2O (1/1, 1 ml) was cooled to 00C. (3-Chloro-2-methylphenyl)methanamine (8.5 mg, 0.055 mmol, 1 equivalent) was added. The reaction mixture was adjusted to a pH of about 9-10 using IN NaOH. Total about 1 equivalent of base was required. LC- MS was used to monitor the reaction. Within about 1 hour, the reaction was completed. Without work-up and purification, it was used for the next amine addition in the same reaction vessel. MS: calcd for C11H9C13N4+H+ 302.99, found 303.07.
Preparation of (lr,4r)-4-((4-chloro-6-(2,3-dimethylbenzylamino)-l,3,5-triazin-2- ylamino)methyl)-Λ7-(4-(<V-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000119_0001
To the reaction solution of preparation of 4,6-dichloro-N-(2,3-dimethylbenzyl)- l,3,5-triazin-2-amine (0.11 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 2 ml) was added (lr,4r)-4-(aminomethyl)-N-(4-(N-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide as the TFA salt (44.7 mg, 0.085 mmol, 0.85 equivalent). IN NaOH was added to the reaction to adjust the pH to about 9-10. The reaction mixture was stirred at room temperature overnight. Without work-up, the desired product was used directly in the next step. MS: calcd for C29H34C1Ν9O3S2+H4 656.19, found 656.15.
Preparation of (lr,4r)-4-((4-chloro-6-(3-chloro-2-methylbenzylamino)-l,3,5-triazin- 2-ylamino)methyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000119_0002
To the reaction solution of preparation of 4,6-dichloro-N-(3-chloro-2- methylbenzyl)-l,3,5-triazin-2-amine (0.055 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 1 mL) was added (lr,4r)-4-(aminomethyl)-N-(4-(N-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide as the TFA salt (22.4 mg, 0.043 mmol, 0.8 equivalent). IN NaOH was added to the reaction to adjust the pH to about 9-10. The reaction mixture was stirred at room temperature overnight. Without work-up, the desired product was used directly in the next step. MS: calcd for C28H31C12Ν9O3S2+H+ 676.14, found 676.12.
Preparation of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000120_0001
To the reaction solution of preparation of (lr,4r)-4-((4-chloro-6-(2,3- dimethylbenzylamino)-l,3,5-triazin-2-ylamino)methyl)-N-(4-(N-(5-methyl- 1,3,4- thiadiazol-2-yl)sulfamoyl)phenyl)cyclohexanecarboxamide (0.055 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 1 ml) was added benzylamine (54.1 mg, 0.55 mmol, 10 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction mixture was neutralized and purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-70% CH3CN/H2O, 0.1% TFA, 19 min) to give the desired product (5.25 mg, 13% in 3 steps). MS: calcd for C36H42N10O3S2+H+ 727.29, found 727.35.
Preparation of (lr,4r)-4-((4-(2,3-dimethylbenzylamino)-6-(methylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000120_0002
To the reaction solution of preparation of (lr,4r)-4-((4-chloro-6-(2,3- dimethylbenzylamino)-l,3,5-triazin-2-ylamino)methyl)-N-(4-(N-(5-methyl- 1,3,4- thiadiazol-2-yl)sulfamoyl)phenyl)cyclohexanecarboxamide (0.055 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 1 ml) was added methylamine (40% in water, 43 μl, 0.55 mmol, 10 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction mixture was neutralized and directly purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20- 70% CH3CN/H2O, 0.1% TFA, 19 min) to give the desired product (1.23 mg, yield 3.5% in 3 steps). MS: calcd for C30H38N10O3S2+H+ 651.26, found 651.29.
Preparation of (lr,4r)-4-((4-(2-(dimethylamino)ethylamino)-6-(2,3- dimethylbenzylamino)-l,3?5-triazin-2-ylamino)methyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4- thiadiazol^-yOsulfamoyOphenyOcyclohexanecarboxamide
Figure imgf000121_0001
To the reaction solution of preparation of (lr,4r)-4-((4-chloro-6-(2,3- dimethylbenzylamino)-l,3,5-triazin-2-ylamino)methyl)-N-(4-(N-(5-methyl- 1,3,4- thiadiazol-2-yl)sulfamoyl)phenyl)cyclohexanecarboxamide (0.054 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 1 ml) was added N,N-dimethylethylenediamine (48 mg, 0.55 mmol, 10 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction mixture was neutralized with IN HCl and purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-65% CH3CΝ/H2O, 0.1% TFA, 19 min) to give desired product (5.6 mg, yield 12.4% in 3 steps). MS: calcd for C33H45N11O3S2+H+ 708.31, found 708.35. Preparation of (lr,4r)-4-((4-(benzylamino)-6-(3-chloro-2-methylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ^-(4-(Λ^-(5-methyl-l,3,4-thiadiazol-2- yl)sulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000122_0001
To the reaction solution of preparation of (lr,4r)-4-((4-chloro-6-(3-chloro-2- methylbenzylamino)- 1,3, 5-triazin-2-ylamino)methyl)-N-(4-(N-(5-methyl- 1,3,4- thiadiazol-2-yl)sulfamoyl)phenyl)cyclohexanecarboxamide (0.055 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 1 ml) was added benzylamine (54.1 mg, 0.55 mmol, 10 equivalents). The reaction mixture was heated at 8O0C overnight. The reaction mixture was neutralized and purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 25-85% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product (1.05 mg, 2.6% in 3 steps). MS: calcd for C35H39ClN10O3S2+H+ 747.23, found 747.31.
Scheme 8
Figure imgf000123_0001
Preparation of (lr,4r)-4-((4-chloro-6-(2,3-dimethylbenzylamino)-l,3,5-triazin-2- ylamino)methyl)cyclohexanecarboxylic acid
Figure imgf000123_0002
To the reaction solution of preparation of 4,6-dichloro-N-(2,3-dimethylbenzyl)- l,3,5-triazin-2-amine (2.5 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 20 niL) was added trans 4-aminomethyl cyclohexanecarboxylic acid (393 mg, 2.5 mmol, 1 equivalent). IN NaOH was added to the reaction to adjust the pH to about 9-10. The reaction mixture was stirred at room temperature overnight. Without work-up, the desired product was used directly in the next step. MS: calcd for C20H26ClN5O2+H+ 404.18, found 404.13. Preparation of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)cyclohexanecarboxylic acid
Figure imgf000124_0001
To the reaction solution of preparation of (lr,4r)-4-((4-chloro-6-(2,3- dimethylbenzylamino)-l,3,5-triazin-2-ylamino)methyl)cyclohexanecarboxylic acid (2.5 mmol, 1 equivalent) in CH3CN/H2O (-1/1, -40 ml) was added benzylamine (2.7 g, 25 mmol, 10 equivalents). The reaction mixture was heated at 800C overnight. The solvent was evaporated and the residue was acidified and purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 20-80% CH3CN/H2O, 0.1% TFA, 25 min) to give the desired product (847.8 mg, yield 71.5% in 3 steps). MS: calcd for C27H34N6O2+H+ 475.27, found 475.38.
Preparation of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ^-(4-(Λ^-thiazol-2- ylsulfamoyl)phenyl)cyclohexanecarboxamide
Figure imgf000124_0002
A solution of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)cyclohexanecarboxylic acid (40 mg, 0.084 mmol, 1 equivalent), 4-amino-N-(thiazol-2-yl)benzenesulfonamide (24.5 mg, 0.096 mmol, 1.14 equivalents) and DMAP (2.1 mg, 0.017 mmol, 0.2 equivalent) in dichloromethane (1 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-
(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 20.2 mg, 0.105 mmol, 1.25 equivalents) was added. The reaction mixture was stirred at 00C for 30 minutes and at room temperature overnight. The solution was diluted with dichloromethane (1 ml), which was further washed with saturated sodium bicarbonate and water. The solvent was removed in vacuo to give the crude which was further purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 5-80% CH3CN/H2O, 0.1% TFA, 25 min) to give the desired product (45.6 mg, yield 76%). MS: calcd for C36H41N9O3S2+H+ 712.28, found 712.4.
Preparation of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ^-(4-sulfamoylphenyl)cyclohexanecarboxamide
Figure imgf000125_0001
A solution of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)cyclohexanecarboxylic acid (40 mg, 0.084 mmol, 1 equivalent), 4-aminobenzenesulfonamide (16.5 mg, 0.096 mmol, 1.14 equivalents) and DMAP (2.1 mg, 0.017 mmol, 0.2 equivalent) in dichloromethane (1 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 20.2 mg, 0.105 mmol, 1.25 equivalents) was added. The reaction mixture was stirred at 00C for 30 minutes and at room temperature overnight. The solution was diluted with dichloromethane (1 ml), which was further washed with saturated sodium bicarbonate and water. The solvent was removed in vacuo to give the crude which was further purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 5-80% CH3CN/H2O, 0.1% TFA, 25 min) to give the desired product (12.4, yield 24%) MS: calcd for C33H40N8O3S+H+ 629.29, found 629.4. Preparation of (Ir ,4r)-Λ^-(4-(Λ^-acetylsulfamoyl)phenyl)-4-((4-(benzylamino)-6-(2,3- dimethylbenzylamino)-l,3,5-triazin-2-ylamino)methyl)cyclohexanecarboxamide
Figure imgf000126_0001
A solution of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)cyclohexanecarboxylic acid (40 mg, 0.084 mmol, 1 equivalent), N-(4-aminophenylsulfonyl)acetamide (20.6 mg, 0.096 mmol, 1.14 equivalents) and DMAP (2.1 mg, 0.017 mmol, 0.2 equivalent) in dichloromethane (1 mL) was cooled with stirring in an ice bath. l-Ethyl-3-[3-
(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 20.2 mg, 0.105 mmol, 1.25 equivalents) was added. The reaction mixture was stirred at 00C for 30 minutes and at room temperature overnight. The solution was diluted with dichloromethane (1 ml), which was further washed with saturated sodium bicarbonate and water. The solvent was removed in vacuo to give the crude which was further purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 5-80% CH3CΝ/H2O, 0.1% TFA, 30 min) to give the desired product (14.2, yield 25%) MS: calcd for C35H42N8O4S+H+ 671.31, found 671.4.
Preparation of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylcyclohexanecarboxamide
Figure imgf000127_0001
A solution of (lr,4r)-4-((4-(benzylamino)-6-(2,3-dimethylbenzylamino)-l,3,5- triazin-2-ylamino)methyl)cyclohexanecarboxylic acid (40 mg, 0.084 mmol, 1 equivalent), N-ethyl m-toluidine (13 mg, 0.096 mmol, 1.14 equivalents) and DMAP (2.1 mg, 0.017 mmol, 0.2 equivalent) in dichloromethane (1 ml) was cooled with stirring in an ice bath. l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI, 20.2 mg, 0.105 mmol, 1.25 equivalents) was added. The reaction mixture was stirred at 00C for 30 minutes and at room temperature overnight. The solution was diluted with dichloromethane (1 ml), which was further washed with saturated sodium bicarbonate and water. The solvent was removed in vacuo to give the crude which was further purified by RP-HPLC (Luna, 5μ C8(2), 100x21mm, 5-80% CH3CΝ/H2O, 0.1% TFA, 25 min) to give the desired product (29.1 mg, yield 59%) MS: calcd for C36H45N7O+H+ 592.37, found 592.4.
Scheme 9
Figure imgf000127_0002
General procedure for the first amine addition
A mixture of cyanuric chloride (577.7 mg, 3.13 mmol, 1 equivalent) in CH3CN/H2O (1/1, 40 ml) was cooled to 00C. The first amine (1 equivalent) was added. The reaction mixture was adjusted to a pH of about 9-10 using IN NaOH. The reaction was continued stirring at cold until the completion of the reaction, monitored by LC-MS. Without workup, the solution will be used directly for the second amine addition.
Example of a preparation of 4,6-dichloro-jV-(l-(3-methoxyphenyl)ethyl)-l,3,5- triazin-2-amine
Figure imgf000128_0001
Following the above general procedure, cyanuric chloride (577.7 mg, 3.13 mmol, 1 equivalent) in CH3CN/H2O (1/1, 40 ml) was allowed to undergo reaction with l-(3- methoxyphenyl)ethanamine (437.7 mg, 3.13 mmol, 1 equivalent) at cold for 30 min to give the desired product. MS: calcd for C12H12C12N4O+H+ 299.04, found 299.0.
Example of a preparation of 2,4-dichloro-6-(4-(5-(trifluoromethyl)pyridin-2- yl)piperazin-l-yl)-l,3,5-triazine
Figure imgf000128_0002
Following the above general procedure, cyanuric chloride (584.9 mg, 3.17 mmol, 1 equivalent) in CH3CN/H2O (1/1, 40 ml) was allowed to undergo reaction with l-(5- (trifluoromethyl)pyridin-2-yl)piperazine (733.4 mg, 3.17 mmol, 1 equivalent) at cold for 1 hour to give the desired product.
General procedure for the second amine addition
To the above solution of first amine addition (~ 1 mmol, 1 equivalent) in CH3CN/H2O (1/1, -15 ml) was added second amine (1 equivalent). The solution was adjusted to a pH of about 9-10 using IN NaOH (~ 1 equivalent). The reaction mixture was stirred at room temperature for about 3-4 hours, monitored by LC-MS. Without workup, the solution will be used directly for the third amine addition.
Example of a preparation of Λ^-benzyl-β-chloro-Λ^-Cl-CS-methoxyphenyOethyl)- l,3,5-triazine-2,4-diamine
Figure imgf000129_0001
Following the above general procedure, the solution of 4,6-dichloro-N-(l-(3- methoxyphenyl)ethyl)-l,3,5-triazin-2-amine (~1 mmol, 1 equivalent) in CHsCΝ/f^O (1/1, -14 ml) was allowed to undergo reaction with benzylamine (113 ul, 1.04 mmol, 1 equivalent) at room temperature for 2 hours to give the desired product. MS: calcd for C19H20ClΝ5O+H+ 370.14, found 370.2.
Example of a preparation of Λ7-benzyl-4-chloro-6-(4-(5-(trifluoromethyl)pyridin-2- yl)piperazin-l-yl)-l,3,5-triazin-2-amine
Figure imgf000129_0002
Following the above general procedure, the solution of 2,4-dichloro-6-(4-(5- (trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazine (~1 mmol, 1 equivalent) in CH3CN/H2O (1/1, -13 ml) was allowed to undergo reaction with benzylamine (109 μl, 1 mmol, 1 equivalent) at room temperature for 3-4 hours to give the desired product.
Example of a preparation of 4-chloro-iV-(2-phenoxyethyl)-6-(4-(5- (trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazin-2-amine
Figure imgf000130_0001
Following the above general procedure, the solution of 2,4-dichloro-6-(4-(5- (trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazine (~1 mmol, 1 equivalent) in CH3CN/H2O (1/1, -13 ml) was allowed to undergo reaction with 2-phenoxyethanamine (137 mg, 1 mmol, 1 equivalent) at room temperature for 3-4 hours to give the desired product.
General procedure for the third amine addition
To the above solution of second amine addition (~ 0.2 mmol, 1 equivalent) in CH3CN/H2O (1/1, ~2 ml) was added third amine (2.5 equivalents). IN NaOH (2.5 equivalents) was added if the amine was in HCl salt. The reaction mixture was heated at 8O0C overnight. The solvent was removed in caccuo and the residue was purified with RP-HPLC using TFA buffer.
Example of a preparation of Λ^2-benzyl-Λ^-(l-(3-methoxyphenyl)ethyl)-Λ^-(4- (methylsulfonyl)benzyl)-l,3,5-triazine-2,4,6-triamine
Figure imgf000130_0002
Following the above general procedure, the solution of N^-benzyl-ό-chloro-N4- (l-(3-methoxyphenyl)ethyl)-l,3,5-triazine-2,4-diamine (-0.14 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 2 ml) was allowed to undergo reaction with (4- (methylsulfonyl)phenyl)methanamine as HCl salt (78 mg, 0.35 mmol, 2.5 equivalents) at 8O0C overnight to give the desired product. MS: calcd for C27H30N6O3S+H+ 519.22, found 519.3. Example of a preparation of Λ^2-benzyl-Λ^-(4-tert-butylbenzyl)-Λ^-(l-(3- methoxyphenyl)ethyl)-l,3,5-triazine-2,4,6-triamine
Figure imgf000131_0001
Following the above general procedure, the solution of N^-benzyl-ό-chloro-N4- (l-(3-methoxyphenyl)ethyl)-l,3,5-triazine-2,4-diamine (-0.14 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 2 ml) was allowed to undergo reaction with (4-tert- butylphenyl)methanamine (57 mg, 0.35 mmol, 2.5 equivalents) at 8O0C overnight to give the desired product. MS: calcd for C30H36N6O+H+ 497.30, found 497.4.
Example of a preparation of Λ^2-benzyl-Λ^-(4-fert-butylbenzyl)-6-(4-(5- (trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazine-2,4-diamine
Figure imgf000131_0002
Following the above general procedure, the solution of N-benzyl-4-chloro-6-(4- (5-(trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazin-2-amine (-0.2 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 2 ml) was allowed to undergo reaction with {A-tert- butylphenyl)methanamine (82 mg, 0.5 mmol, 2.5 equivalents) at 8O0C overnight to give the desired product. MS: calcd for C31H35F3N8+H+ 577.30, found 577.4.
Example of a preparation of Λ^2-(4-(methylsulfonyl)benzyl)-Λ^-(2-phenoxyethyl)-6- (4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazine-2,4-diamine
Figure imgf000132_0001
Following the above general procedure, the solution of 4-chloro-N-(2- phenoxyethyl)-6-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-l-yl)-l,3,5-triazin-2- amine (-0.2 mmol, 1 equivalent) in CH3CΝ/H2O (1/1, 2 ml) was allowed to undergo reaction with (4-(methylsulfonyl)phenyl)methanamine as HCl salt (112 mg, 0.5 mmol, 2.5 equivalents) at 800C overnight to give the desired product. MS: calcd for C29H31F3N8O3S+H+ 629.23, found 629.4.
Scheme 8
Figure imgf000132_0002
Preparation of 4-((4-chloro-6-(3,4-dihydroquinolin-l(2H)-yl)-l,3,5-triazin-2- ylamino)methyl)-Λ7-ethyl-Λ7-rø-tolylbenzamide
Figure imgf000133_0001
At 00C, the mixture of cyanuric chloride (50 mg, 0.375 mmol, 1 equivalent) in pH 9.4 borate buffer (0.5 M, 4 ml) was added 1,2,3,4-tetrahydroquinoline (69 mg, 0.375 mmol, 1 equivalent). The pH of the solution was adjusted to about 9-10 with IN NaOH. The reaction was stirred at 4°C overnight. 4-(Aminomethyl)-N-ethyl-N-m- tolylbenzamide as a TFA salt (143 mg, 0.375 mmol, 1 equivalent) was added, followed by adding IN NaOH (30 μl, 0.75 mmol, 2 equivalents). The reaction was heated at 500C for 4-5 hrs. More 4-(Aminomethyl)-N-ethyl-N-m-tolylbenzamide was added to push the reaction to completion. The solvent was evaporated and the crude was purified with RP- HPLC (Luna, 5μ C8(2), 100x21mm, 50-98% CH3CΝ/H2O, 0.1% TFA, 20 min) to give the desired compound (36.8 mg, 19% in 2 steps). MS: calcd for C29H29C1N6O+H+ 513.22, found 513.30.
Preparation of 4-((4-(3,4-dihydroquinolin-l(2H)-yl)-6-(2-(4-methylpiperazin-l- yl)ethylamino)-l,3,5-triazin-2-ylamino)methyl)-Λ^-ethyl-Λ^-rø-tolylbenzamide
Figure imgf000133_0002
To the solution of 4-((4-chloro-6-(3,4-dihydroquinolin-l(2H)-yl)-l,3,5-triazin-2- ylamino)methyl)-N-ethyl-N-m-tolylbenzamide (20 mg, 0.039 mmol, 1 equivalent) in ΝMP (0.5 ml) was added 2-(4-methyl-piperazin-l-yl)-ethylamine (28 mg, 0.195 mmol, 5 equivalents). The reaction mixture was heated at 800C for about 3 hours. The reaction solution was acidified and directly purified with RP-ΗPLC (Luna, 5μ C8(2), 100x21mm, 40-95% CH3CN/H2O, 0.1% TFA, 20 min) to give the desired product as TFA salt (18.9 mg, 57%). MS: calcd for C36H45N9O+H+ 620.83, found 620.5.
EQUIVALENTS
[0010] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
INCORPORATION BY REFERENCE
[0011] The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

Claims

CLAIMSWhat is claimed is:
1. A compound of formula I:
Figure imgf000135_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3-C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NR1R2; Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(Ci-C6)alkyl, heteroaryl, heteroaralkyl, (Ci- Ce)carboxyalkyl, aryloxy(Ci-C6)alkyl,
-alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-C6)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci- Ce)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-Ce)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(Ci-C6)alkyl, heteroaryl, heteroaralkyl, (Ci- Ce)carboxyalkyl, aryloxy(Ci-C6)alkyl,
-alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-Ce)alkyl; R2 is optionally substituted with 1, 2 or 3 (Ci-Ce)alkyl, (Ci- Ce)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or R1 and R2 can be taken together to form a 5-7 membered heterocycle having 1 , 2 or 3 heteroatoms and optionally substituted with Ra;
R3 is hydrogen or (Ci-C6)alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, or -SO2-, -SO2NR4-, or -COO-;
R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3
R12-N groups independently selected from Ra or 11 in which Rn is hydrogen or (Ci-C6) alkyl; R12 is hydrogen, (Ci-C6) alkyl, -CO(Ci-
C6)alkyl, -CO(Ci-C6)cycloalkyl, -CO(Cj -C6)heterocycloalkyl, -CO(Ci-
C6) aryl, -CO(Ci -Ce)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and Ri2 can be taken together to form a 5-7 membered heterocycle having 1 , 2 or 3 heteroatoms and optionally substituted with Ra;
R6 is hydrogen or (Ci-Ce)alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with
1, 2, or 3 groups independently selected from Ra;
R9 is hydrogen, halo or (Ci-C6)alkyl;
Rio is hydrogen or (Ci-Ce)alkyl; or
R9 and Rio together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo, (Ci-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000136_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Zi, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (Ci-C6)alkoxy; Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3- C7)cycloalkyl,
(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2- C6)alkenyloxy, (CrC6)alkynyloxy, (CrC6)alkylthio, (CrC6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl,
-C(=N)(Ci-C6)alkyl, carboxy, CO2(d-C6)alkyl, CONH2, -C(=N)NH2, -C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, -CON((Ci-C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Q- C6)alkyl, -OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci-C6)alkyl, -NH-C(O)NH2, -N(Q-C6)alkyl- C(O)NH2, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl, N(Q-C6)alkyl- C(O)NH(Ci-C6)alkyl)2,
-NH-C(O)NH(Ci -C6)alkyl)2, N-(Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (Ci-C6)alkylsulfonylamino, or N-(Q- C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and
Rc is halogen, trifluoromethyl, trifluoromethoxy, (Q-C6)alkyl, amino, cyano, nitro, or hydroxyl.
2. A compound of formula II:
Figure imgf000137_0001
or a pharmaceutically acceptable salt thereof, wherein:
Ri is hydrogen, (Q-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(Q-C6)alkyl, heteroaryl, heteroaralkyl, (Q- C6)carboxyalkyl, aryloxy(Ci-C6)alkyl,
-alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-C6)alkyl; R1 is optionally substituted with 1, 2 or 3 (CrC6)alkyl, (C1- Ce)alkoxy or (C1-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (C1-Ce)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(C1-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(C1-C6)alkyl, heteroaryl, heteroaralkyl, (C1- Ce)carboxyalkyl, aryloxy(C1-C6)alkyl,
-alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-Ce)alkyl; R2 is optionally substituted with 1, 2 or 3 (Ci-C6)alkyl, (C1- Ce)alkoxy or (C1-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or R1 and R2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (C1-Ce)alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, or -SO2-, -SO2NR4-, or -COO-; R4 is hydrogen or (Ci-Cδjalkyl;
R5 is hydrogen, (Ci-C6)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3
O
R12-N groups independently selected from Ra or 11 in which R11 is hydrogen or (C1-C6) alkyl; R12 is hydrogen, (C1-C6) alkyl, -CO(C1- C6)alkyl, -CO(C1-C6)cycloalkyl, -CO(Ci -C6)heterocycloalkyl, -CO(C1-
Ce) aryl, -CO(Ci -C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra;
R6 is hydrogen or (Ci-Ce)alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (C1-
Ce)alkoxy, either of which may be optionally substituted on carbon with
1, 2, or 3 groups independently selected from Ra;
R9 is hydrogen, halo or (Ci-C6)alkyl;
Rio is hydrogen or (Ci-Ce)alkyl; or
R9 and Ri0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo, (C1-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000139_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-Ce)alkyl, or (Ci-C6)alkoxy; Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (CrC6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3- C7)cycloalkyl,
(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (Ci-C6)alkoxy, (C2- C6)alkenyloxy, (Ci-C6)alkynyloxy, (Ci-C6)alkylthio, (C1-C6)alkylsulfinyl, (Ci-C6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl,
-C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -C(=N)NH2, -C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, -CON((Ci-C6)alkyl)2, -OC(O)(d-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci- C6)alkyl, -OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci-C6)alkyl, -NH-C(O)NH2, -N(Ci-C6)alkyl- C(O)NH2, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl, N(Ci-C6)alkyl- C(O)NH(Ci-C6)alkyl)2,
-NH-C(O)NH(Ci -C6)alkyl)2, N-(d-C6)alkylsulfamoyl,
N,N-di-[(Ci-C6)alkyl]sulfamoyl, (Ci-C6)alkylsulfonylamino, or N-(Q-
C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and
Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
3. A compound of formula III:
Figure imgf000140_0001
or a pharmaceutically acceptable salt thereof, wherein: Y is H, halo, ORi, SRj, (CrC8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3- C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NRiR2;
Ri is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Q- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; Ri is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci-C6)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3-C6)heterocycloalkyl(Ci- Ce)alkyl, heteroaryl, heteroaralkyl, (Ci-C6)carboxyalkyl, aryloxy(Ci-C6)alkyl, - alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci- Ce)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R" ', wherein R" ' is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (CrC6)alkyl, (CrC6)alkoxy or (CrC6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle having 1,
2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-C6)alkyl; m is O, I, or 2;
R4 is hydrogen or (Ci -C6) alkyl;
R6 is hydrogen or (Ci-C6)alkyl;
R7 and R8 are each independently hydrogen, halogen, (Ci-C6)alkyl or (Ci-
Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or
3 groups independently selected from Ra; R9 is hydrogen, halo or (Ci -C6) alkyl; Rio is hydrogen or (Ci-C6)alkyl; or
R9 and Ri0 together with the atoms to which they are attached, form a 4-8 membered ring, optionally substituted on carbon with 1, 2, or 3 groups selected from halo,
(Ci-C6)alkyl, and -O-(d-C6)alkyl, -S-(d-C6)alkyl, any of which may be optionally substituted on carbon with 1, 2, or 3 halo, or taken together with the attached carbon form C=O;
Figure imgf000141_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl;
B is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
Rn is hydrogen or (Ci-C6) alkyl; RJ2 is hydrogen, (Ci-C6) alkyl, -CO(Ci- C6)alkyl, -CO(Cj -C6)cycloalkyl, -CO(Ci-C6)heterocycloalkyl, -CO(Ci-C6) aryl, - CO(Ci-C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or Rn and R12 can be taken together to form a 5-7 membered heterocycle having 1, 2, or 3 heteroatoms having 1, 2 or 3 heteroatoms and optionally substituted with
Ra; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (Ci-C6)alkyl, or (Ci-C6)alkoxy;
Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (Ci-C6)alkyl-NH, ((Ci-C6)alkyl)2-N, aryl, heteroaryl, (C3-C7)cycloalkyl, (C1- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (CrC6)alkoxy, (C2-C6)alkenyloxy, (C1- C6)alkynyloxy, (CrC6)alkylthio, (CrC6)alkylsulfinyl, (CrC6)alkylsulfonyl, amino, (Ci-C6)alkylamino, di-[(Ci-C6)alkyl]amino, formyl, -C(=O)(Ci-C6)alkyl, -C(=N)(Ci-C6)alkyl, carboxy, CO2(Ci-C6)alkyl, CONH2, -C(=N)NH2, - C(=N)NH(Ci-C6)alkyl), -C(=N)N(Ci-C6)alkyl)2, CONH(Ci-C6)alkyl, C0N((d- C6)alkyl)2, -OC(O)(Ci-C6)alkyl, -OC(O)NH2, -OC(O)NH(Ci-C6)alkyl, - OC(O)NH((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -N(Ci-C6)alkyl-C(O)(Ci- C6)alkyl, -NH-C(O)NH2, -N(Ci-C6)alkyl-C(O)NH2, N(Ci-C6)alkyl-C(O)NH(d- C6)alkyl, N(Ci-C6)alkyl-C(O)NH(Ci-C6)alkyl)2, -NH-C(O)NH(Ci-C6)alkyl)2, N- (Ci-C6)alkylsulfamoyl, N,N-di-[(Ci-C6)alkyl]sulfamoyl, (C1- C6)alkylsulfonylamino, or N-(Ci-C6)alkyl-(Ci-C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and Rc is halogen, trifluoromethyl, trifluoromethoxy, (Ci-C6)alkyl, amino, cyano, nitro, or hydroxyl.
4. A compound of formula IV:
Figure imgf000142_0001
or a pharmaceutically acceptable salt thereof, wherein:
Y is H, halo, ORi, SRi, (d-C8)alkyl, (C3-C6)cycloalkyl, aryl, aralkyl, (C3-C6)heterocycloalkyl, heteroaryl, heteroaralkyl, or NRiR2; Ri is hydrogen, (Ci-Ce)alkyl, aryl, aralkyl, (C3-Ce)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(Ci-C6)alkyl, heteroaryl, heteroaralkyl, (C1- Ce)carboxyalkyl, aryloxy(Ci-C6)alkyl, -alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4, 5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-Ce)alkyl; Ri is optionally substituted with 1, 2 or 3 (Ci-C6)alkyl, (Ci- Ce)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra;
R2 is hydrogen, (Ci-Ce)alkyl, aryl, aralkyl, (C3-C6)cycloalkyl, (C3- C6)cycloalkyl(Ci-C6)alkyl, (C3-C6)heterocycloalkyl, (C3- C6)heterocycloalkyl(Ci-C6)alkyl, heteroaryl, heteroaralkyl, (Ci- Ce)carboxyalkyl, aiyloxy(Ci-C6)alkyl,
-alkylene-NR'R", wherein R' and R" are each independently hydrogen, (Ci-C6)alkyl, or taken together with the nitrogen to which they are attached, form a 3, 4,
5, or 6-membered saturated or partially unsaturated ring optionally containing 0, 1, or 2 additional heteroatoms selected from O, S(O)x, wherein x is 0, 1, or 2, or N-R' ", wherein R' " is hydrogen or (Ci-C6)alkyl; R2 is optionally substituted with 1, 2 or 3 (d-C6)alkyl, (Ci- Ce)alkoxy or (Ci-C6)haloalkyl or 1, 2 or 3 groups independently selected from Ra; or Ri and R2 can be taken together to form a 5-7 membered heterocycle having 1, 2 or 3 heteroatoms and optionally substituted with Ra; R3 is hydrogen or (Ci-Ce)alkyl; m is 0, 1, or 2;
X is absent, -CONR4-, or -SO2-, -SO2NR4-, or -COO-; R4 is hydrogen or (Ci-C6)alkyl;
R5 is hydrogen, (Ci-Ce)alkyl, (C3-C6)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3
groups independently selected from Ra or
Figure imgf000143_0001
in which Rn is hydrogen or (Ci-C6) alkyl; RJ2 is hydrogen, (Ci-C6) alkyl, -CO(Ci- C6)alkyl, -CO(Ci-C6)cycloalkyl, -CO(Cj -C6)heterocycloalkyl, -CO(C1- Ce) aryl, -CO(Ci -C6)heteroaryl, cycloalkyl, aryl, or heteroaryl, any of which may be optionally substituted with 1, 2, or 3 groups independently selected from Ra; or R11 and R12 can be taken together to form a 5-7 membered heterocycle having 1 , 2 or 3 heteroatoms and optionally substituted with Ra; Re is hydrogen or (C1-Ce)alkyl; n is 0, 1, 2 or 3;
R7 and R8 are each independently hydrogen, halogen, (CrC6)alkyl or (C1- Ce)alkoxy, either of which may be optionally substituted on carbon with 1, 2, or 3 groups independently selected from Ra;
Figure imgf000144_0001
is aryl, aryloxy, heteroaryl, cycloalkyl, or heterocycloalkyl; at least two of three of Z1, Z2, and Z3 are N and the other is C-Rb, wherein Rb is hydrogen, halogen, (CrCόjalkyl, or (CrCβjalkoxy; Ra is halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, (C1-C6)alkyl-NH, ((C1-C6)alkyl)2-N, aryl, heteroaryl, (C3- C7)cycloalkyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1- C6)alkoxy, (C2-C6)alkenyloxy, (C1-C6)alkynyloxy, (C1-C6)alkylthio, (C1- C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, amino, (C1-C6)alkylamino, di- [(C1-C6)alkyl]amino, formyl, -C(=O)(C1-C6)alkyl, -C(=N)(C1-C6)alkyl, carboxy, CO2(C1-C6)alkyl, CONH2, -C(=N)NH2, -Q=N)NH(C1- C6)alkyl), -Q=N)N(C1 -C6)alkyl)2, CONH(C1-C6)alkyl, C0N((Cr C6)alkyl)2, -OC(O)(C1-C6)alkyl, -OC(O)NH2, -OC(O)NH(C1-C6)alkyl, - OC(O)NH((CrC6)alkyl)2, -NHC(O)(CrC6)alkyl, -N(CrC6)alkyl- C(O)(C1-C6)alkyl, -NH-C(O)NH2, -N(C1-C6)alkyl-C(O)NH2, N(C1- C6)alkyl-C(O)NH(C1-C6)alkyl, N(C1-C6)alkyl-C(O)NH(C1-C6)alkyl)2, - NH-C(O)NH(C1-C6)alkyl)2, N-(C1-C6)alkylsulfamoyl, N,N-di-[(Cr C6)alkyl]sulfamoyl, (C1-C6)alkylsulfonylamino, or N-(C1-C6)alkyl-(C1- C6)alkylsulfonylamino, any of which may be optionally substituted on carbon with Rc, and
Rc is halogen, trifluoromethyl, trifluoromethoxy, (C1-Ce)alkyl, amino, cyano, nitro, or hydroxyl. mpound selected from the group consisting of:
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
-153-
Figure imgf000155_0001
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof.
7. A method for treating or preventing an inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, thereby treating or preventing said inflammatory disorder. A method of treating a condition or disease mediated by aggrecanase in a mammalian subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, thereby treating said condition or disease.
A method of treating a subject suffering from a disease selected from the group consisting of osteoarthritis, joint injury, reactive arthritis, acute pyrophosphate arthritis, psoriatic arthritis and rheumatoid arthritis, comprising administering to the subject a therapeutically effective amount of a compound of any of the preceding claims or a pharmaceutically acceptable salt thereof, thereby treating said subject.
PCT/US2009/031575 2009-01-21 2009-01-21 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors Ceased WO2010085246A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2009/031575 WO2010085246A1 (en) 2009-01-21 2009-01-21 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/031575 WO2010085246A1 (en) 2009-01-21 2009-01-21 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors

Publications (1)

Publication Number Publication Date
WO2010085246A1 true WO2010085246A1 (en) 2010-07-29

Family

ID=40810148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/031575 Ceased WO2010085246A1 (en) 2009-01-21 2009-01-21 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors

Country Status (1)

Country Link
WO (1) WO2010085246A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024489A3 (en) * 2010-08-18 2012-06-07 Emory University Compounds and compositions for ossification and methods related thereto
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CN104903312A (en) * 2013-10-07 2015-09-09 卡德门企业有限公司 Rho kinase inhibitors
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
CN109438473A (en) * 2018-12-07 2019-03-08 武汉工程大学 A kind of Ofloxacin-sulfacetamide heterozygosis drug and its preparation method and application
WO2021214637A1 (en) * 2020-04-20 2021-10-28 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053595A1 (en) * 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2003007930A2 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
WO2003031431A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20030139416A1 (en) * 2001-04-11 2003-07-24 Buchanan John L. Substituted triazinyl acrylamide derivatives and methods of use
US20030191307A1 (en) * 1999-11-30 2003-10-09 Blumenkopf Todd A. 2,4-Diaminopyrimidine compounds useful as immunosuppressants
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2006034473A2 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2007109045A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
WO2008063671A2 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053595A1 (en) * 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
US20030191307A1 (en) * 1999-11-30 2003-10-09 Blumenkopf Todd A. 2,4-Diaminopyrimidine compounds useful as immunosuppressants
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20030139416A1 (en) * 2001-04-11 2003-07-24 Buchanan John L. Substituted triazinyl acrylamide derivatives and methods of use
WO2003007930A2 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
WO2003031431A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2006034473A2 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2007109045A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
WO2008063671A2 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PANDYA, U. H. ET AL: "Studies on s-triazine derivatives - Part I", XP002475637, retrieved from STN Database accession no. 1981:515470 *
IRIKURA TSUTOMU ET AL: "New s-Triazine Derivatives as Depressants for Reticuloendothelial Hyperfunction Induced by Bacterial Endotoxin", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 13, no. 6, 1970, pages 1081 - 1089, XP002465111, ISSN: 0022-2623 *
JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA) , 53(2), 69-70 CODEN: JOICA7; ISSN: 0020-3254, 1981 *
LÖWIK D W P M ET AL: "Synthesis of Macrocyclic, Triazine-Based Receptor Molecules", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, WILEY-VCH VERLAG, WEINHEIM, DE, 2001, pages 2825 - 2839, XP002274796, ISSN: 1434-193X *
SCHUERER, STEPHAN C. ET AL: "Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space", JOURNAL OF CHEMICAL INFORMATION AND MODELING , 45(2), 239-248 CODEN: JCISD8; ISSN: 1549-9596, 2005, XP002475631 *
ZHENG ET AL: "Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 15, no. 4, 14 January 2007 (2007-01-14), pages 1815 - 1827, XP005830443, ISSN: 0968-0896 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8614213B2 (en) 2008-08-07 2013-12-24 Novartis Ag Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists
US10537577B2 (en) 2010-08-18 2020-01-21 Emory University Compounds and compositions for ossification and methods related thereto
CN103153352A (en) * 2010-08-18 2013-06-12 爱默蕾大学 Compounds and compositions for ossification and methods related thereto
CN103153352B (en) * 2010-08-18 2015-07-15 爱默蕾大学 Compounds and compositions for ossification and methods related thereto
WO2012024489A3 (en) * 2010-08-18 2012-06-07 Emory University Compounds and compositions for ossification and methods related thereto
US11844802B2 (en) 2010-08-18 2023-12-19 Emory University Compounds and compositions for ossification and methods related thereto
US9511071B2 (en) 2010-08-18 2016-12-06 Emory University Compounds and compositions for ossification and methods related thereto
US11471461B2 (en) 2010-08-18 2022-10-18 Emory University Compounds and compositions for ossification and methods related thereto
US9808464B2 (en) 2010-08-18 2017-11-07 Emory University Compounds and compositions for ossification and methods related thereto
US10888565B2 (en) 2010-08-18 2021-01-12 Emory University Compounds and compositions for ossification and methods related thereto
CN104903312A (en) * 2013-10-07 2015-09-09 卡德门企业有限公司 Rho kinase inhibitors
CN104903312B (en) * 2013-10-07 2019-01-29 卡德门企业有限公司 RHO kinase inhibitor
US10125144B2 (en) 2013-10-07 2018-11-13 Kadmon Corporation, Llc Rho kinase inhibitors
JP2016534038A (en) * 2013-10-07 2016-11-04 カドモン コーポレイション，リミティド ライアビリティ カンパニー RHO kinase inhibitor
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
CN109438473A (en) * 2018-12-07 2019-03-08 武汉工程大学 A kind of Ofloxacin-sulfacetamide heterozygosis drug and its preparation method and application
WO2021214637A1 (en) * 2020-04-20 2021-10-28 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases
US20230201208A1 (en) * 2020-04-20 2023-06-29 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases

Similar Documents

Publication Publication Date Title
KR101456721B1 (en) New compounds
AU2002220195B2 (en) Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP4589529B2 (en) Indole derivatives as factor XA inhibitors
CA2267224C (en) Vitronectin receptor antagonists
WO2010085246A1 (en) 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors
US6743810B2 (en) Indol-3-yl derivatives
ES2282195T3 (en) DERIVATIVES OF INDOL.
PT1400518E (en) Heterocyclic compound derivatives and medicines
ES2295048T3 (en) BIS-SULFONAMIDS.
CA2923484C (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
JP2009514926A (en) Carbocyclic fused ring amines as inhibitors of coagulation factor Xa
HUP0101333A2 (en) Diazepan derivatives and their salts, pharmaceutical compositions containing the same
JP6434528B2 (en) Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
AU760246B2 (en) Beta-alanine derivatives
WO2018192866A1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2097378B1 (en) Novel seh inhibitors and their use
ES2266233T3 (en) SULFONAMIDS ARILETENO, ITS PREPARATION AND ITS USE AS AN ENDOTHELINE ANTAGONIST.
JP2010515699A (en) Sulfonamide derivatives as chymase inhibitors
WO2002009711A1 (en) Thrombin inhibitors
JP2008536850A (en) VLA-4 antagonist
WO2001055133A1 (en) Substituted tryptophan derivatives
HUP0105477A2 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases and their use for preparation of pharmaceutical compositions
US20040138284A1 (en) Indol-3-yl derivatives
JP4624616B2 (en) Benzimidazole compounds
RU2471783C2 (en) Sulphonamide derivatives as chymase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09789432

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09789432

Country of ref document: EP

Kind code of ref document: A1